citalopram has been researched along with Disease Models, Animal in 218 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although escitalopram is known to be an effective drug for adult depression, its disease-modifying efficacy on adolescents remains controversial." | 8.31 | Effects of Escitalopram on the Functional Neural Circuits in an Animal Model of Adolescent Depression. ( Choi, JY; Han, SJ; Kang, KJ; Lee, N; Nam, KR; Oh, SJ, 2023) |
| "In the current study, we investigated the protective role of citalopram against cognitive decline, impaired mitochondrial dynamics, defective mitochondrial biogenesis, defective autophagy, mitophagy and synaptic dysfunction in APP transgenic mouse model of Alzheimer's disease (ad)." | 8.02 | Selective serotonin reuptake inhibitor citalopram ameliorates cognitive decline and protects against amyloid beta-induced mitochondrial dynamics, biogenesis, autophagy, mitophagy and synaptic toxicities in a mouse model of Alzheimer's disease. ( Bunquin, LE; Kshirsagar, S; Morton, H; Reddy, AP; Reddy, PH; Sawant, N; Yin, X, 2021) |
| " A treatment with escitalopram reversed depression-like behavior accompanied by reductions in BDNF levels in serum and the nucleus accumbens, while a treatment with blonanserin ameliorated abnormal social interaction behavior with reductions in serum BDNF levels." | 7.91 | Antidepressant activities of escitalopram and blonanserin on prenatal and adolescent combined stress-induced depression model: Possible role of neurotrophic mechanism change in serum and nucleus accumbens. ( Deriha, K; Furuse, K; Hashiguchi, H; Hashimoto, E; Ishii, T; Kawanishi, C; Kigawa, Y; Shiraishi, M; Tayama, M; Ukai, W, 2019) |
| " In this study, we examined the molecular effects associated with a response to a week-long treatment with escitalopram in the chronic escape deficit (CED) model, a validated model of depression based on the induction of an escape deficit after exposure of rats to an unavoidable stress." | 7.88 | Molecular changes associated with escitalopram response in a stress-based model of depression. ( Alboni, S; Benatti, C; Blom, JMC; Brunello, N; Mendlewicz, J; Tascedda, F, 2018) |
| "The obtained results suggest that ADs may enhance the antipsychotic-like effect of aripiprazole in the animal tests used for evaluation of some positive and cognitive symptoms of schizophrenia." | 7.88 | Combined treatment with aripiprazole and antidepressants reversed some MK-801-induced schizophrenia-like symptoms in mice. ( Lorenc-Koci, E; Rogóż, Z; Wąsik, A, 2018) |
| " The aim of the present study was to investigate whether stress-induced anhedonia could be prevented by treatments with escitalopram or novel herbal treatment (NHT) in an animal model of depression." | 7.85 | Escitalopram and NHT normalized stress-induced anhedonia and molecular neuroadaptations in a mouse model of depression. ( Barak, S; Burstein, O; Chen, G; Doron, R; Franko, M; Gale, E; Handelsman, A; Hirshler, Y; Motsan, S; Shamir, A; Simhon, O; Toledano, R, 2017) |
| " The current study investigated whether administration of citalopram to pregnant rats could prevent anxiety and depressive-like behaviour induced by gestational stress in their offspring, and restore the expression of serotonin 1A autoreceptors in GABAergic interneurons in the medial prefrontal cortex and dorsal raphe nuclei in males, and of corticotropin-releasing factor type 2 receptors in GABAergic interneurons in the dorsal raphe nuclei in females." | 7.83 | Perinatal citalopram does not prevent the effect of prenatal stress on anxiety, depressive-like behaviour and serotonergic transmission in adult rat offspring. ( Shoham, S; Weinstock, M; Zohar, I, 2016) |
| "Considering the gene X environment hypothesis of depression, the present study investigated the effect of chronic ozone inhalation on depression and anxiety-related behavior, cognition, and brain markers of oxidative stress in the Flinders Sensitive Line (FSL) rat." | 7.81 | Ozone exposure of Flinders Sensitive Line rats is a rodent translational model of neurobiological oxidative stress with relevance for depression and antidepressant response. ( Brink, CB; Ellis, SM; Harvey, BH; Mokoena, ML; Viljoen, F, 2015) |
| "Female rats implanted with 28-day osmotic minipumps delivering the SSRI escitalopram throughout pregnancy had serum escitalopram concentrations in a clinically observed range (17-65 ng/ml)." | 7.79 | Prenatal exposure to escitalopram and/or stress in rats: a prenatal stress model of maternal depression and its treatment. ( Boss-Williams, KA; Bourke, CH; Capello, CF; Owens, MJ; Rogers, SM; Stowe, ZN; Weiss, JM; Yu, ML, 2013) |
| " We investigated the antiallodynic and antihyperalgesic effects of intrathecally administered morphine, citalopram, paroxetine, and combinations thereof, in a rat model in which peripheral inflammation was induced by complete Freund's adjuvant (CFA)." | 7.78 | Interaction of morphine and selective serotonin receptor inhibitors in rats experiencing inflammatory pain. ( Jun, IG; Kim, SH; Lee, BS; Park, JY, 2012) |
| " The aim of this study was to assess the antiarthritic potential of 2 SSRIs, fluoxetine and citalopram, in murine collagen-induced arthritis (CIA) and in a human ex vivo disease model of rheumatoid arthritis (RA)." | 7.76 | Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. ( Brennan, F; Gregory, B; Medghalchi, M; Sacre, S; Williams, R, 2010) |
| "We investigated the hypothesis that hippocampal neurogenesis related to Notch1 signaling could be a valid index for a combined citalopram and WAY100635 pharmacotherapy for the treatment of depression arising after stroke." | 7.76 | Notch1 signaling related hippocampal neurogenesis in adult poststroke depression rats: a valid index for an efficient combined citalopram and WAY100635 pharmacotherapy. ( Guo, YJ; Sui, YX; Sun, Y; Wang, SH; Zhang, ZJ, 2010) |
| " Therefore, aggression was tested in male CFW mice to determine whether repeated citalopram (CIT) administration reduces alcohol-heightened aggression." | 7.74 | Long-term citalopram maintenance in mice: selective reduction of alcohol-heightened aggression. ( Caldwell, EE; Miczek, KA, 2008) |
| "In order to study the gene-environment interaction as well as investigate prophylactic/ameliorative effects of early intervention on development of adult life psychopathology, we superimposed maternal separation on an animal model of depression the Flinders Sensitive Line (FSL) rats and their controls the Flinders Resistant Line (FRL) rats and studied behavior following treatment with escitalopram." | 7.73 | Adult life behavioral consequences of early maternal separation are alleviated by escitalopram treatment in a rat model of depression. ( El Khoury, A; Gruber, SH; Mathé, AA; Mørk, A, 2006) |
| "The effects of acute, systemic administration of amitriptyline, duloxetine and mirtazapine (antidepressant drugs that variously affect extracellular noradrenaline and serotonin levels) and the selective serotonin reuptake inhibitor (SSRI) citalopram were compared in rat models of experimental pain." | 7.73 | Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. ( Blackburn-Munro, G; Bomholt, SF; Mikkelsen, JD, 2005) |
| "Citalopram-treated animals (n = 13) showed a significant increase in impaired forepaw use in the staircase task compared with saline-treated animals (n = 12) 2, 3 and 7 weeks post stroke but no difference in neurological score at any time point examined." | 5.72 | Delayed citalopram administration reduces brain inflammation and enhances skilled motor function after ischaemic stroke in 'MacGreen' mice. ( Bennet, L; Chen, S; McGregor, AL, 2022) |
| "Depression is characterized by significant and low mood." | 5.56 | Folic acid ameliorates depression-like behaviour in a rat model of chronic unpredictable mild stress. ( Cong, Y; Liu, H; Zhou, Y, 2020) |
| "Citalopram treatment altered levels of select components of the cellular protein homeostatic machinery that may be expected to enhance the capacity to refold and/or degrade mutant ATXN3." | 5.51 | Citalopram Reduces Aggregation of ATXN3 in a YAC Transgenic Mouse Model of Machado-Joseph Disease. ( Ashraf, NS; Costa, MDC; Duarte-Silva, S; Maciel, P; Paulson, HL; Shaw, ED; Teixeira-Castro, A, 2019) |
| "Posttraumatic stress disorder (PTSD) is a trauma-induced mental disorder characterised by fear extinction dysfunction in which fear circuit monoamines are possibly associated." | 5.43 | Escitalopram reversed the traumatic stress-induced depressed and anxiety-like symptoms but not the deficits of fear memory. ( Lin, CC; Liu, YP; Tung, CS, 2016) |
| " This practice of polypharmacy increases the possibility for drug-drug interactions." | 5.38 | Drug-drug conditioning between citalopram and haloperidol or olanzapine in a conditioned avoidance response model: implications for polypharmacy in schizophrenia. ( Li, M; Sparkman, NL, 2012) |
| "Escitalopram treatment did not effect the reduced levels of NR2B resulting from depression." | 5.37 | Effects of venlafaxine and escitalopram treatments on NMDA receptors in the rat depression model. ( Cure, MC; Demirdas, A; Eren, I; Kirbas, A; Sutcu, R; Yilmaz, M; Yilmaz, N, 2011) |
| "In this regard, we used a model of clonic seizures induced by pentylenetetrazole (PTZ) in male NMRI mice to investigate whether morphine and citalopram exhibit additive anticonvulsant effects and, if so, whether this effect is mediated through modulation of 5-HT(3) receptors." | 5.37 | The role of 5-HT(3) receptors in the additive anticonvulsant effects of citalopram and morphine on pentylenetetrazole-induced clonic seizures in mice. ( Bahremand, A; Dehpour, AR; Ebrahimi, A; Fakhfouri, G; Ghasemi, A; Ghasemi, M; Loloee, S; Payandemehr, B; Pourmand, N; Rahimian, R; Ziai, P, 2011) |
| "One hypothesis of depression is that it is caused by reduced neuronal plasticity including hippocampal neurogenesis." | 5.36 | The antidepressant effects of running and escitalopram are associated with levels of hippocampal NPY and Y1 receptor but not cell proliferation in a rat model of depression. ( Bjørnebekk, A; Brené, S; Mathé, AA, 2010) |
| " In the clinical study, sarcosine substantially improved scores of Hamilton Depression Rating Scale, Clinical Global Impression, and Global Assessment of Function more than citalopram treatment." | 5.17 | Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. ( Chang, YC; Chen, KT; Huang, CC; Huang, CL; Huang, KH; Lane, HY; Tsai, GE; Tsai, MH; Tsai, P; Tun, R; Wei, IH, 2013) |
| "Although escitalopram is known to be an effective drug for adult depression, its disease-modifying efficacy on adolescents remains controversial." | 4.31 | Effects of Escitalopram on the Functional Neural Circuits in an Animal Model of Adolescent Depression. ( Choi, JY; Han, SJ; Kang, KJ; Lee, N; Nam, KR; Oh, SJ, 2023) |
| " Alleviation of anhedonia was assessed in chronic mild stress model using sucrose preference test." | 4.12 | Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization. ( Abraham, R; Gagginapally, SR; Goura, V; Goyal, VK; Jasti, V; Jayarajan, P; Kallepalli, R; Medapati, RB; Mohammed, AR; Nirogi, R; Palacharla, VRC; Pandey, SK; Petlu, S; Subramanian, R; Tadiparthi, J; Thentu, JB, 2022) |
| "In the current study, we investigated the protective role of citalopram against cognitive decline, impaired mitochondrial dynamics, defective mitochondrial biogenesis, defective autophagy, mitophagy and synaptic dysfunction in APP transgenic mouse model of Alzheimer's disease (ad)." | 4.02 | Selective serotonin reuptake inhibitor citalopram ameliorates cognitive decline and protects against amyloid beta-induced mitochondrial dynamics, biogenesis, autophagy, mitophagy and synaptic toxicities in a mouse model of Alzheimer's disease. ( Bunquin, LE; Kshirsagar, S; Morton, H; Reddy, AP; Reddy, PH; Sawant, N; Yin, X, 2021) |
| "Intranasal treatment with oxytocin showed beneficial effects in post-traumatic stress disorder and autism spectrum disorders; however, it was not investigated as much in depression." | 4.02 | Synergy of oxytocin and citalopram in modulating Itgb3/Chl1 interplay: Relevance to sensitivity to SSRI therapy. ( Batinić, B; Gurwitz, D; Israel-Elgali, I; Jukić, M; Oved, K; Pešić, V; Puškaš, N; Shomron, N; Stanić, D, 2021) |
| "We performed in vivo microdialysis and in vivo 2-photon imaging to assess changes in brain interstitial fluid (ISF) Aβ and Aβ plaque size over time, respectively, in the APP/presenilin 1 mouse model of Alzheimer disease treated with vehicle or escitalopram." | 3.96 | Effect of escitalopram on Aβ levels and plaque load in an Alzheimer mouse model. ( Cirrito, JR; Davis, TA; Doherty, BM; Gardiner, WD; King, D; Lee, JM; Sheline, YI; Wallace, CE; Yan, P; Yuede, CM, 2020) |
| "A recent review proposed four criteria for an animal model of treatment-resistant depression (TRD): a phenotypic resemblance to a risk factor for depression; enhanced response to stress; nonresponse to antidepressant drugs and response to treatments effective in TRD, such as deep brain stimulation (DBS) of the prefrontal cortex or ketamine." | 3.91 | Validation of chronic mild stress in the Wistar-Kyoto rat as an animal model of treatment-resistant depression. ( Gruca, P; Lason, M; Litwa, E; Niemczyk, M; Papp, M; Tota-Glowczyk, K; Willner, P, 2019) |
| "We therefore superimposed maternal separation (MS) onto a genetic rat model (Flinders-sensitive and -resistant lines, FSL/FRL) of depression, treated these rats with antidepressants (escitalopram and nortriptyline) and measured CGRP-LI in selected brain regions." | 3.91 | CGRP in a gene-environment interaction model for depression: effects of antidepressant treatment. ( Angelucci, F; El Khoury, A; Ellenbroek, BA; Mathé, AA, 2019) |
| " A treatment with escitalopram reversed depression-like behavior accompanied by reductions in BDNF levels in serum and the nucleus accumbens, while a treatment with blonanserin ameliorated abnormal social interaction behavior with reductions in serum BDNF levels." | 3.91 | Antidepressant activities of escitalopram and blonanserin on prenatal and adolescent combined stress-induced depression model: Possible role of neurotrophic mechanism change in serum and nucleus accumbens. ( Deriha, K; Furuse, K; Hashiguchi, H; Hashimoto, E; Ishii, T; Kawanishi, C; Kigawa, Y; Shiraishi, M; Tayama, M; Ukai, W, 2019) |
| " In this study, we examined the molecular effects associated with a response to a week-long treatment with escitalopram in the chronic escape deficit (CED) model, a validated model of depression based on the induction of an escape deficit after exposure of rats to an unavoidable stress." | 3.88 | Molecular changes associated with escitalopram response in a stress-based model of depression. ( Alboni, S; Benatti, C; Blom, JMC; Brunello, N; Mendlewicz, J; Tascedda, F, 2018) |
| "The obtained results suggest that ADs may enhance the antipsychotic-like effect of aripiprazole in the animal tests used for evaluation of some positive and cognitive symptoms of schizophrenia." | 3.88 | Combined treatment with aripiprazole and antidepressants reversed some MK-801-induced schizophrenia-like symptoms in mice. ( Lorenc-Koci, E; Rogóż, Z; Wąsik, A, 2018) |
| "Depression and substance cocaine abuse are disorders with a high frequency of comorbidity." | 3.85 | Effects of escitalopram and imipramine on cocaine reinforcement and drug-seeking behaviors in a rat model of depression. ( Filip, M; Frankowska, M; Jastrzębska, J; Nowak, E; Przegaliński, E; Suder, A; Wydra, K, 2017) |
| " The aim of the present study was to investigate whether stress-induced anhedonia could be prevented by treatments with escitalopram or novel herbal treatment (NHT) in an animal model of depression." | 3.85 | Escitalopram and NHT normalized stress-induced anhedonia and molecular neuroadaptations in a mouse model of depression. ( Barak, S; Burstein, O; Chen, G; Doron, R; Franko, M; Gale, E; Handelsman, A; Hirshler, Y; Motsan, S; Shamir, A; Simhon, O; Toledano, R, 2017) |
| " Moreover we also investigated their utility as adjunct treatment in depression in combination with the SSRI citalopram." | 3.83 | Alpha7 nicotinic acetylcholine receptor agonists and PAMs as adjunctive treatment in schizophrenia. An experimental study. ( Björkholm, C; Feltmann, K; Jardemark, K; Konradsson-Geuken, Å; Malmerfelt, A; Marcus, MM; Möller, A; Påhlsson, N; Schilström, B; Svensson, TH, 2016) |
| " The current study investigated whether administration of citalopram to pregnant rats could prevent anxiety and depressive-like behaviour induced by gestational stress in their offspring, and restore the expression of serotonin 1A autoreceptors in GABAergic interneurons in the medial prefrontal cortex and dorsal raphe nuclei in males, and of corticotropin-releasing factor type 2 receptors in GABAergic interneurons in the dorsal raphe nuclei in females." | 3.83 | Perinatal citalopram does not prevent the effect of prenatal stress on anxiety, depressive-like behaviour and serotonergic transmission in adult rat offspring. ( Shoham, S; Weinstock, M; Zohar, I, 2016) |
| "Considering the gene X environment hypothesis of depression, the present study investigated the effect of chronic ozone inhalation on depression and anxiety-related behavior, cognition, and brain markers of oxidative stress in the Flinders Sensitive Line (FSL) rat." | 3.81 | Ozone exposure of Flinders Sensitive Line rats is a rodent translational model of neurobiological oxidative stress with relevance for depression and antidepressant response. ( Brink, CB; Ellis, SM; Harvey, BH; Mokoena, ML; Viljoen, F, 2015) |
| "5, 5 or 10mg/kg) significantly reversed depression-like behaviours in chronically stressed rats, including reduced sucrose preference, decreased locomotor activity, and prolonged time to begin eating." | 3.81 | The antidepressant-like pharmacological profile of Yuanzhi-1, a novel serotonin, norepinephrine and dopamine reuptake inhibitor. ( Chen, HX; Gao, N; Jin, ZL; Li, XR; Li, YF; Tang, Y; Xiong, J; Xue, R, 2015) |
| " AP521 showed equal or more potent anxiolytic-like effects compared with diazepam, a benzodiazepine receptor agonist, or tandospirone, a partial 5-hydroxytryptamine (5-HT)1A receptor agonist, in three rat anxiety models; the Vogel-type conflict test, elevated plus maze test, and conditioned fear stress test." | 3.81 | The effects of AP521, a novel anxiolytic drug, in three anxiety models and on serotonergic neural transmission in rats. ( Hashimoto, S; Hattori, T; Kasahara, K; Kawakubo, H; Kawasaki, K; Nagatani, T; Nakazono, O; Takao, K; Tsujita, R, 2015) |
| "Both Bifidobacteria and escitalopram reduced anxiety in the marble burying test; however, only B." | 3.80 | Bifidobacteria exert strain-specific effects on stress-related behavior and physiology in BALB/c mice. ( Cryan, JF; Dinan, TG; Kiely, B; Savignac, HM, 2014) |
| "Female rats implanted with 28-day osmotic minipumps delivering the SSRI escitalopram throughout pregnancy had serum escitalopram concentrations in a clinically observed range (17-65 ng/ml)." | 3.79 | Prenatal exposure to escitalopram and/or stress in rats: a prenatal stress model of maternal depression and its treatment. ( Boss-Williams, KA; Bourke, CH; Capello, CF; Owens, MJ; Rogers, SM; Stowe, ZN; Weiss, JM; Yu, ML, 2013) |
| " We investigated the antiallodynic and antihyperalgesic effects of intrathecally administered morphine, citalopram, paroxetine, and combinations thereof, in a rat model in which peripheral inflammation was induced by complete Freund's adjuvant (CFA)." | 3.78 | Interaction of morphine and selective serotonin receptor inhibitors in rats experiencing inflammatory pain. ( Jun, IG; Kim, SH; Lee, BS; Park, JY, 2012) |
| " Citalopram significantly decreased the spontaneous seizure frequency at the highest dose tested, that is, the mean number of seizures decreased from 12." | 3.78 | The antidepressants citalopram and reboxetine reduce seizure frequency in rats with chronic epilepsy. ( Clinckers, R; Massie, A; Smolders, I; Vermoesen, K, 2012) |
| "The purpose of this study was to analyze the antidepressant-like actions of estradiol valerate (1 or 2 mg/rat, single injection) or citalopram (5 or 10 mg/kg, chronically administered for 21 days) given independently or combined at low doses, to middle-aged ovariectomized female rats, as a model of human menopause." | 3.76 | Estradiol valerate elicits antidepressant-like effects in middle-aged female rats under chronic mild stress. ( Fernández-Guasti, A; Romano-Torres, M, 2010) |
| "We investigated the hypothesis that hippocampal neurogenesis related to Notch1 signaling could be a valid index for a combined citalopram and WAY100635 pharmacotherapy for the treatment of depression arising after stroke." | 3.76 | Notch1 signaling related hippocampal neurogenesis in adult poststroke depression rats: a valid index for an efficient combined citalopram and WAY100635 pharmacotherapy. ( Guo, YJ; Sui, YX; Sun, Y; Wang, SH; Zhang, ZJ, 2010) |
| " The aim of this study was to assess the antiarthritic potential of 2 SSRIs, fluoxetine and citalopram, in murine collagen-induced arthritis (CIA) and in a human ex vivo disease model of rheumatoid arthritis (RA)." | 3.76 | Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. ( Brennan, F; Gregory, B; Medghalchi, M; Sacre, S; Williams, R, 2010) |
| " Therefore, aggression was tested in male CFW mice to determine whether repeated citalopram (CIT) administration reduces alcohol-heightened aggression." | 3.74 | Long-term citalopram maintenance in mice: selective reduction of alcohol-heightened aggression. ( Caldwell, EE; Miczek, KA, 2008) |
| " The aim of this study was to investigate the effects of the SSRIs citalopram and fluoxetine, on the corticocerebral blood flow (cCBF) in rabbits with unilateral carotid occlusion induced cerebral ischemia." | 3.74 | Effects of citalopram and fluoxetine on the corticocerebral blood flow in conscious rabbits. ( Csete, K; Papp, JG; Sas, K; Sztriha, L; Vécseil, L; Vezekényi, Z, 2007) |
| "The effects of acute, systemic administration of amitriptyline, duloxetine and mirtazapine (antidepressant drugs that variously affect extracellular noradrenaline and serotonin levels) and the selective serotonin reuptake inhibitor (SSRI) citalopram were compared in rat models of experimental pain." | 3.73 | Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. ( Blackburn-Munro, G; Bomholt, SF; Mikkelsen, JD, 2005) |
| "The purpose of the present study was to elucidate the brain regions in which citalopram, a selective serotonin reuptake inhibitor (SSRI), exerts its anxiolytic effects in conditioned fear stress (CFS) in rats, an animal model of anxiety." | 3.73 | Target brain sites of the anxiolytic effect of citalopram, a selective serotonin reuptake inhibitor. ( Inoue, T; Izumi, T; Kitaichi, Y; Koyama, T; Nakagawa, S, 2006) |
| "In order to study the gene-environment interaction as well as investigate prophylactic/ameliorative effects of early intervention on development of adult life psychopathology, we superimposed maternal separation on an animal model of depression the Flinders Sensitive Line (FSL) rats and their controls the Flinders Resistant Line (FRL) rats and studied behavior following treatment with escitalopram." | 3.73 | Adult life behavioral consequences of early maternal separation are alleviated by escitalopram treatment in a rat model of depression. ( El Khoury, A; Gruber, SH; Mathé, AA; Mørk, A, 2006) |
| " During exposure to hypoxia (10% O2 for 2 weeks), the animals received one of the specific 5-HTT inhibitors citalopram and fluoxetine (10 mg/kg/day), the selective 5-HT1B/1D receptor antagonist GR127935 (2 and 10 mg/kg/day), or the 5-HT2A receptor antagonist ketanserin (2 mg/kg/day)." | 3.72 | Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. ( Adnot, S; Eddahibi, S; Hamon, M; Marcos, E; Nosjean, A; Pham, MH; Raffestin, B, 2003) |
| "Citalopram-treated animals (n = 13) showed a significant increase in impaired forepaw use in the staircase task compared with saline-treated animals (n = 12) 2, 3 and 7 weeks post stroke but no difference in neurological score at any time point examined." | 1.72 | Delayed citalopram administration reduces brain inflammation and enhances skilled motor function after ischaemic stroke in 'MacGreen' mice. ( Bennet, L; Chen, S; McGregor, AL, 2022) |
| "Depression is characterized by significant and low mood." | 1.56 | Folic acid ameliorates depression-like behaviour in a rat model of chronic unpredictable mild stress. ( Cong, Y; Liu, H; Zhou, Y, 2020) |
| "Citalopram is a selective serotonin reuptake inhibitor, and although widely used as an antidepressant, this drug has also demonstrated interesting repairing properties leading to motor recovery and pathology amelioration in animal models of stroke and degeneration." | 1.56 | Citalopram Administration Does Not Promote Function or Histological Recovery after Spinal Cord Injury. ( Assunção-Silva, R; Gomes, ED; Lima, R; Monteiro, S; Morais, M; Salgado, AJ; Silva, NA; Vasconcelos, NL, 2020) |
| "In particularly, the methods evaluating hearing disorders are not well established in animal models, limiting the pre-clinical research on its mechanism." | 1.56 | Attenuation of auditory mismatch negativity in serotonin transporter knockout mice with anxiety-related behaviors. ( Chen, F; Chen, P; Li, C; Lyu, K; Pan, W; Tang, J; Ying, M; Zhang, H, 2020) |
| "Citalopram treatment altered levels of select components of the cellular protein homeostatic machinery that may be expected to enhance the capacity to refold and/or degrade mutant ATXN3." | 1.51 | Citalopram Reduces Aggregation of ATXN3 in a YAC Transgenic Mouse Model of Machado-Joseph Disease. ( Ashraf, NS; Costa, MDC; Duarte-Silva, S; Maciel, P; Paulson, HL; Shaw, ED; Teixeira-Castro, A, 2019) |
| " Application of new drugs which could enhance the effectiveness of antidepressants drug and reduce side effects of their long-term use seems necessary." | 1.48 | Influence of citicoline on citalopram-induced antidepressant activity in depressive-like symptoms in male mice. ( Akhondzadeh, S; Nejatisafa, AA; Roohi-Azizi, M; Sadat-Shirazi, MS; Torkaman-Boutorabi, A; Zarrindast, MR, 2018) |
| " Here we investigated the effects of chronic administration of caffeine (5mg/kg, twice daily for 14days) and its withdrawal on day 15th on the activity of per se ineffective doses of fluoxetine (5mg/kg) and escitalopram (2mg/kg) given on day 15th." | 1.46 | Chronic treatment with caffeine and its withdrawal modify the antidepressant-like activity of selective serotonin reuptake inhibitors in the forced swim and tail suspension tests in mice. Effects on Comt, Slc6a15 and Adora1 gene expression. ( Doboszewska, U; Dudka, J; Herbet, M; Kanadys, A; Korga, A; Ostrowska, M; Poleszak, E; Serefko, A; Świąder, K; Szopa, A; Terlecka, J; Wlaź, A; Wlaź, P; Wośko, S; Wróbel, A; Wyska, E, 2017) |
| "Diazepam, however, was more effective than escitalopram in suppressing MB." | 1.46 | Marble burying as compulsive behaviors in male and female mice. ( Chourbaji, S; Lerch, S; Taylor, GT, 2017) |
| " Chronic administration of amitriptyline reversed the despaired behavior induced by exposure to UCMS paradigm and, fully recovered pNF-H labeling to control values." | 1.46 | Effect of amitriptyline treatment on neurofilament-H protein in an experimental model of depression. ( Galeotti, N; Ghelardini, C; Sanna, MD, 2017) |
| "Escitalopram treatments reduced escape latency, elevated platform crossing times, improved CA1 neuronal damage, increased DA and 5-HT levels in hippocampal and cortical neurons, as well as elevated expression of 5-HT1AR mRNA (P < 0." | 1.43 | Effect of selective serotonin reuptake inhibitors on expression of 5-HT1AR and neurotransmitters in rats with vascular dementia. ( Guo, K; Pan, Q; Yin, G; Zhu, HX; Zi, XH, 2016) |
| "Depression is a common mental illness and a leading cause of disability." | 1.43 | Essential Contributions of Serotonin Transporter Inhibition to the Acute and Chronic Actions of Fluoxetine and Citalopram in the SERT Met172 Mouse. ( Blakely, RD; McMeekin, AM; Moussa-Tooks, AB; Nackenoff, AG; Veenstra-VanderWeele, J, 2016) |
| "Posttraumatic stress disorder (PTSD) is a trauma-induced mental disorder characterised by fear extinction dysfunction in which fear circuit monoamines are possibly associated." | 1.43 | Escitalopram reversed the traumatic stress-induced depressed and anxiety-like symptoms but not the deficits of fear memory. ( Lin, CC; Liu, YP; Tung, CS, 2016) |
| "Treatment with citalopram versus saline was applied via osmotic pump after coronary artery ligation." | 1.43 | Early citalopram treatment increases mortality due to left ventricular rupture in mice after myocardial infarction. ( Ertl, G; Frantz, S; Frey, A; Hofmann, U; Lehmann, M; Lesch, KP; Mathes, D; Pachel, C; Popp, S; Saxon, VM, 2016) |
| " Whether similar observations would occur after repeated administration of such compounds in an attempt to simulate dosing in humans, or be compromised by dopaminergic-mediated adverse effects warrants further investigation." | 1.42 | Antinociceptive activity of the new triple reuptake inhibitor NS18283 in a mouse model of chemotherapy-induced neuropathic pain. ( Coudoré, F; Gardier, AM; Guiard, BP; Hache, G; Munro, G; Nguyen, TH; Peters, D; Quesseveur, G, 2015) |
| " However, a long term use of ketamine tends to elicit its adverse reactions." | 1.42 | Repeated ketamine administration redeems the time lag for citalopram's antidepressant-like effects. ( Guo, J; Liu, WX; Qiu, LL; Sun, HL; Wang, XM; Yang, JJ; Zhang, GF; Zhou, ZQ, 2015) |
| "Depression during pregnancy has been linked to in utero stress and is associated with long-lasting symptoms in offspring, including anxiety, helplessness, attentional deficits, and social withdrawal." | 1.42 | Prenatal stress, regardless of concurrent escitalopram treatment, alters behavior and amygdala gene expression of adolescent female rats. ( Bourke, CH; Ehrlich, DE; Hazra, R; Jairam, N; Neigh, GN; Nemeth, CL; Owens, MJ; Rainnie, DG; Rowson, S; Ryan, SJ; Sholar, CA; Stowe, ZN, 2015) |
| "Current treatments for depression are characterized by a low success rate and associated with a wide variety of side effects." | 1.40 | A novel herbal treatment reduces depressive-like behaviors and increases BDNF levels in the brain of stressed mice. ( Doron, R; Einat, N; Kately, N; Lotan, D; Marom, I; Meron, G; Rehavi, M; Winer, A; Yaffe, R, 2014) |
| "Escitalopram treatment decreased anxiety-related behaviours in stressed animals, by increasing the time spent in the central part of the arena with respect to saline treated stressed animals, without affecting exploratory related behaviours." | 1.40 | Behavioural and transcriptional effects of escitalopram in the chronic escape deficit model of depression. ( Alboni, S; Benatti, C; Blom, JM; Brunello, N; Gandolfi, F; Mendlewicz, J; Tascedda, F, 2014) |
| "Depression is the leading psychiatric disorder with a high risk of morbidity and mortality." | 1.40 | Chronic but not acute antidepresant treatment alters serum zinc/copper ratio under pathological/zinc-deficient conditions in mice. ( Krakowska, A; Mlyniec, K; Nowak, G; Opoka, W; Ostachowicz, B; Reczynski, W, 2014) |
| "Pretreatment with citalopram, a selective 5-HT reuptake inhibitor (2." | 1.39 | Increasing brain serotonin corrects CO2 chemosensitivity in methyl-CpG-binding protein 2 (Mecp2)-deficient mice. ( Abdala, AP; Bissonnette, JM; Knopp, SJ; Paton, JF; Toward, MA, 2013) |
| " This hypermethylated pattern was reversed to normal, as indicated by the control line, after chronic administration of escitalopram (a selective serotonin reuptake inhibitor; SSRI)." | 1.38 | Antidepressant treatment is associated with epigenetic alterations in the promoter of P11 in a genetic model of depression. ( Björk, K; Lavebratt, C; Lennartsson, A; Mathé, AA; Melas, PA; Qi, H; Rogdaki, M; Svenningsson, P; Wegener, G; Werme, M; Witasp, A, 2012) |
| "SSR180711 is a recently described α7 nAChR agonist that has shown antidepressant-like activity in the rat forced swim test." | 1.38 | Combined α7 nicotinic acetylcholine receptor agonism and partial serotonin transporter inhibition produce antidepressant-like effects in the mouse forced swim and tail suspension tests: a comparison of SSR180711 and PNU-282987. ( Andreasen, JT; Nielsen, EØ; Redrobe, JP, 2012) |
| " This practice of polypharmacy increases the possibility for drug-drug interactions." | 1.38 | Drug-drug conditioning between citalopram and haloperidol or olanzapine in a conditioned avoidance response model: implications for polypharmacy in schizophrenia. ( Li, M; Sparkman, NL, 2012) |
| " To assess the predictive validity of this behavior as a potential marker of "despair," we tested the effects of chronic administration of two common antidepressant drugs on this measure." | 1.38 | Antidepressants reduce extinction-induced withdrawal and biting behaviors: a model for depressive-like behavior. ( Huq, Y; Huston, JP; Komorowski, M; Topic, B; van den Brink, J, 2012) |
| " We compared different phenotypes from the chronic mild stress (CMS) model of depression using chronic administration with two selective serotonin reuptake inhibitors (SSRIs), escitalopram and sertraline." | 1.38 | Vesicular signalling and immune modulation as hedonic fingerprints: proteomic profiling in the chronic mild stress depression model. ( Bak, S; Bisgaard, CF; Christensen, T; Enghild, JJ; Jensen, ON; Wiborg, O, 2012) |
| "In this regard, we used a model of clonic seizures induced by pentylenetetrazole (PTZ) in male NMRI mice to investigate whether morphine and citalopram exhibit additive anticonvulsant effects and, if so, whether this effect is mediated through modulation of 5-HT(3) receptors." | 1.37 | The role of 5-HT(3) receptors in the additive anticonvulsant effects of citalopram and morphine on pentylenetetrazole-induced clonic seizures in mice. ( Bahremand, A; Dehpour, AR; Ebrahimi, A; Fakhfouri, G; Ghasemi, A; Ghasemi, M; Loloee, S; Payandemehr, B; Pourmand, N; Rahimian, R; Ziai, P, 2011) |
| "Escitalopram treatment did not effect the reduced levels of NR2B resulting from depression." | 1.37 | Effects of venlafaxine and escitalopram treatments on NMDA receptors in the rat depression model. ( Cure, MC; Demirdas, A; Eren, I; Kirbas, A; Sutcu, R; Yilmaz, M; Yilmaz, N, 2011) |
| " Depression-related transcriptomic changes in gene expression profiles were investigated in laser-captured microdissected (LCM) rat hippocampal granular cell layers (GCL) using the chronic mild stress (CMS) rat model of depression and chronic administration of two selective serotonin reuptake inhibitors (SSRIs), escitalopram and sertraline." | 1.37 | Biomarkers of anhedonic-like behavior, antidepressant drug refraction, and stress resilience in a rat model of depression. ( Bisgaard, CF; Christensen, T; Wiborg, O, 2011) |
| "Escitalopram treatment restored some but not all alterations observed in FSL rats after early-life stress." | 1.36 | Early-life stress and antidepressant treatment involve synaptic signaling and Erk kinases in a gene-environment model of depression. ( El Khoury, A; Gruber, SH; Mallei, A; Mathé, AA; Musazzi, L; Popoli, M; Racagni, G; Tardito, D, 2010) |
| "One hypothesis of depression is that it is caused by reduced neuronal plasticity including hippocampal neurogenesis." | 1.36 | The antidepressant effects of running and escitalopram are associated with levels of hippocampal NPY and Y1 receptor but not cell proliferation in a rat model of depression. ( Bjørnebekk, A; Brené, S; Mathé, AA, 2010) |
| "Neuropathic pain is characterized by pain hypersensitivity to innocuous stimuli (tactile allodynia) that is nearly always resistant to known treatments such as non-steroidal anti-inflammatory drugs or even opioids." | 1.35 | Antidepressants inhibit P2X4 receptor function: a possible involvement in neuropathic pain relief. ( Imai, T; Inoue, K; Nagata, K; Tozaki-Saitoh, H; Tsuda, M; Yamashita, T, 2009) |
| "Escitalopram treatment was effective at decreasing escape latency times in all ages tested." | 1.35 | Treatment with escitalopram but not desipramine decreases escape latency times in a learned helplessness model using juvenile rats. ( Anderson, JC; Bylund, DB; El Refaey, H; Happe, HK; Petty, F; Reed, AL, 2009) |
| "Mecamylamine was effective on its own in some tests, but did not augment the effects of citalopram or reboxetine at the doses tested." | 1.35 | Nicotine, but not mecamylamine, enhances antidepressant-like effects of citalopram and reboxetine in the mouse forced swim and tail suspension tests. ( Andreasen, JT; Redrobe, JP, 2009) |
| "The citalopram treatment produced unexpected results in the FRL rats: 5-HT synthesis was elevated not only in most of the terminal areas, but also in the cell body areas, the DR and MR." | 1.35 | Acute citalopram has different effects on regional 5-HT synthesis in FSL, FRL, and SDP rats: an autoradiographic evaluation. ( Diksic, M; Hasegawa, S; Kanemaru, K; Nishi, K, 2008) |
| " CMS induced behavioural changes in the ischemic animals, including decreased locomotor and rearing activity and reduced sucrose preference (compared with baseline, control and stroke groups respectively), all these behaviours were reversed by chronic administration of citalopram." | 1.35 | Anhedonia and activity deficits in rats: impact of post-stroke depression. ( Chen, BA; Guo, YJ; Teng, GJ; Wang, SH; Zhang, ZJ; Zhou, H, 2009) |
| "Citalopram prevented the increase in sucrose consumption in the PCA+CVS rats, and in 5-HT-depleted animals blocked the increase in struggling and reduced the number of defecations in the forced swim test." | 1.35 | Rat behavior after chronic variable stress and partial lesioning of 5-HT-ergic neurotransmission: effects of citalopram. ( Eller, M; Häidkind, R; Harro, J; Kõiv, K; Mällo, T; Tõnissaar, M, 2008) |
| "Post-traumatic stress disorder (PTSD) is an anxiety disorder that may develop after the experiencing or witnessing of a life-threatening event." | 1.35 | WFS1 gene as a putative biomarker for development of post-traumatic syndrome in an animal model. ( Gispan, I; Kesner, Y; Merenlender, A; Shalit, F; Yadid, G; Zohar, J, 2009) |
| "Treatment with desipramine or imipramine, however, was not effective at reducing immobility in the 21-day-old rats." | 1.35 | Juvenile rats in the forced-swim test model the human response to antidepressant treatment for pediatric depression. ( Bylund, DB; Happe, HK; Petty, F; Reed, AL, 2008) |
| "Depression is the most common psychiatric complication in Parkinson's disease (PD)." | 1.34 | Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats. ( Juckel, G; Klein, J; Kupsch, A; Lee, T; Morgenstern, R; Mundt, A; Petrus, D; von Rumohr, A; Winter, C, 2007) |
| "R-citalopram has been shown to counteract the 5-HT enhancing properties of escitalopram in acute studies in animals." | 1.32 | R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. ( Gruca, P; Papp, M; Sánchez, C, 2003) |
| "Escitalopram is a very selective 5-HT reuptake inhibitor." | 1.32 | Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. ( Bergqvist, PB; Brennum, LT; Gupta, S; Hogg, S; Larsen, A; Sánchez, C; Wiborg, O, 2003) |
| "Pretreatment with buspirone (0." | 1.30 | Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test. ( Bourin, M; Redrobe, JP, 1998) |
| " El mouse convulsions were inhibited by chronic administration of citalopram (80 mg/kg/day, p." | 1.29 | Chronic administration of citalopram inhibited El mouse convulsions and decreased monoamine oxidase-A activity. ( Endo, A; Kabuto, H; Kurimoto, T; Mori, A; Takei, M; Yokoi, I, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (3.67) | 18.2507 |
| 2000's | 52 (23.85) | 29.6817 |
| 2010's | 139 (63.76) | 24.3611 |
| 2020's | 19 (8.72) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Chen, S | 1 |
| Bennet, L | 1 |
| McGregor, AL | 1 |
| Nirogi, R | 1 |
| Abraham, R | 1 |
| Jayarajan, P | 1 |
| Goura, V | 1 |
| Kallepalli, R | 1 |
| Medapati, RB | 1 |
| Tadiparthi, J | 1 |
| Goyal, VK | 1 |
| Pandey, SK | 1 |
| Subramanian, R | 1 |
| Petlu, S | 1 |
| Thentu, JB | 1 |
| Palacharla, VRC | 1 |
| Gagginapally, SR | 1 |
| Mohammed, AR | 1 |
| Jasti, V | 1 |
| Li, Q | 2 |
| Zhao, W | 1 |
| Liu, S | 2 |
| Zhao, Y | 1 |
| Pan, W | 2 |
| Wang, X | 1 |
| Liu, Z | 1 |
| Xu, Y | 1 |
| Oh, SJ | 1 |
| Lee, N | 1 |
| Nam, KR | 1 |
| Kang, KJ | 1 |
| Han, SJ | 1 |
| Choi, JY | 1 |
| Lyu, K | 1 |
| Zhang, H | 2 |
| Li, C | 1 |
| Chen, P | 1 |
| Ying, M | 1 |
| Chen, F | 1 |
| Tang, J | 1 |
| van Staden, C | 1 |
| de Brouwer, G | 1 |
| Botha, TL | 1 |
| Finger-Baier, K | 1 |
| Brand, SJ | 1 |
| Wolmarans, D | 1 |
| Marchetti, L | 1 |
| Lauria, M | 2 |
| Caberlotto, L | 1 |
| Musazzi, L | 3 |
| Popoli, M | 5 |
| Mathé, AA | 14 |
| Domenici, E | 5 |
| Carboni, L | 6 |
| Zhou, Y | 1 |
| Cong, Y | 1 |
| Liu, H | 1 |
| Lima, R | 1 |
| Monteiro, S | 1 |
| Gomes, ED | 1 |
| Vasconcelos, NL | 1 |
| Assunção-Silva, R | 1 |
| Morais, M | 2 |
| Salgado, AJ | 1 |
| Silva, NA | 1 |
| Pischedda, F | 1 |
| Piccoli, G | 1 |
| Cirrito, JR | 1 |
| Wallace, CE | 1 |
| Yan, P | 1 |
| Davis, TA | 1 |
| Gardiner, WD | 1 |
| Doherty, BM | 1 |
| King, D | 1 |
| Yuede, CM | 1 |
| Lee, JM | 1 |
| Sheline, YI | 1 |
| Odland, AU | 1 |
| Kristensen, JL | 1 |
| Andreasen, JT | 5 |
| Reddy, AP | 3 |
| Yin, X | 2 |
| Sawant, N | 2 |
| Reddy, PH | 2 |
| Morton, H | 1 |
| Kshirsagar, S | 1 |
| Bunquin, LE | 1 |
| Stanić, D | 1 |
| Oved, K | 1 |
| Israel-Elgali, I | 1 |
| Jukić, M | 1 |
| Batinić, B | 1 |
| Puškaš, N | 1 |
| Shomron, N | 1 |
| Gurwitz, D | 1 |
| Pešić, V | 1 |
| Burstein, O | 2 |
| Simon, N | 1 |
| Simchon-Tenenbaum, Y | 1 |
| Rehavi, M | 2 |
| Franko, M | 2 |
| Shamir, A | 2 |
| Doron, R | 3 |
| Minchew, HM | 1 |
| Radabaugh, HL | 1 |
| LaPorte, ML | 1 |
| Free, KE | 1 |
| Cheng, JP | 1 |
| Bondi, CO | 1 |
| Dionisie, V | 1 |
| Ciobanu, AM | 1 |
| Toma, VA | 1 |
| Manea, MC | 1 |
| Baldea, I | 1 |
| Olteanu, D | 1 |
| Sevastre-Berghian, A | 1 |
| Clichici, S | 1 |
| Manea, M | 1 |
| Riga, S | 1 |
| Filip, GA | 1 |
| Minami, S | 1 |
| Satoyoshi, H | 2 |
| Ide, S | 2 |
| Inoue, T | 3 |
| Yoshioka, M | 1 |
| Minami, M | 2 |
| Hale, MW | 2 |
| Lukkes, JL | 2 |
| Dady, KF | 2 |
| Kelly, KJ | 2 |
| Paul, ED | 2 |
| Smith, DG | 2 |
| Raison, CL | 2 |
| Lowry, CA | 2 |
| Pałucha-Poniewiera, A | 1 |
| Podkowa, K | 1 |
| Lenda, T | 1 |
| Pilc, A | 1 |
| Jastrzębska, J | 1 |
| Frankowska, M | 1 |
| Suder, A | 1 |
| Wydra, K | 1 |
| Nowak, E | 1 |
| Filip, M | 1 |
| Przegaliński, E | 2 |
| Nagano, R | 1 |
| Nagano, M | 1 |
| Nakai, A | 1 |
| Takeshita, T | 1 |
| Suzuki, H | 1 |
| Koek, W | 1 |
| Mitchell, NC | 1 |
| Daws, LC | 1 |
| Benatti, C | 2 |
| Alboni, S | 2 |
| Blom, JMC | 1 |
| Mendlewicz, J | 2 |
| Tascedda, F | 2 |
| Brunello, N | 2 |
| Szopa, A | 2 |
| Doboszewska, U | 1 |
| Herbet, M | 1 |
| Wośko, S | 2 |
| Wyska, E | 2 |
| Świąder, K | 2 |
| Serefko, A | 2 |
| Korga, A | 1 |
| Wlaź, A | 1 |
| Wróbel, A | 1 |
| Ostrowska, M | 1 |
| Terlecka, J | 1 |
| Kanadys, A | 1 |
| Poleszak, E | 2 |
| Dudka, J | 1 |
| Wlaź, P | 2 |
| Gale, E | 1 |
| Handelsman, A | 1 |
| Barak, S | 1 |
| Motsan, S | 1 |
| Toledano, R | 1 |
| Simhon, O | 1 |
| Hirshler, Y | 1 |
| Chen, G | 2 |
| Taylor, GT | 1 |
| Lerch, S | 1 |
| Chourbaji, S | 1 |
| Zhang, Q | 1 |
| Yang, C | 1 |
| Liu, T | 2 |
| Liu, L | 1 |
| Li, F | 1 |
| Cai, Y | 2 |
| Lv, K | 1 |
| Li, X | 2 |
| Gao, J | 1 |
| Sun, D | 1 |
| Xu, H | 2 |
| Yang, Q | 1 |
| Fan, X | 2 |
| Wang, M | 1 |
| Huang, W | 1 |
| Gao, T | 1 |
| Zhao, X | 1 |
| Lv, Z | 1 |
| Neyazi, A | 1 |
| Theilmann, W | 1 |
| Brandt, C | 1 |
| Rantamäki, T | 1 |
| Matsui, N | 1 |
| Rhein, M | 1 |
| Kornhuber, J | 1 |
| Bajbouj, M | 1 |
| Sperling, W | 1 |
| Bleich, S | 1 |
| Frieling, H | 1 |
| Löscher, W | 1 |
| Perez-Palomar, B | 1 |
| Mollinedo-Gajate, I | 1 |
| Berrocoso, E | 1 |
| Meana, JJ | 1 |
| Ortega, JE | 1 |
| Steyn, SF | 1 |
| Harvey, BH | 6 |
| Brink, CB | 2 |
| Sanchez, C | 6 |
| El Khoury, A | 4 |
| Hassan, M | 1 |
| Wegener, G | 3 |
| Rogóż, Z | 1 |
| Wąsik, A | 1 |
| Lorenc-Koci, E | 1 |
| Misrani, A | 1 |
| Tabassum, S | 1 |
| Chen, X | 1 |
| Tan, SY | 1 |
| Wang, JC | 1 |
| Yang, L | 1 |
| Long, C | 1 |
| Roohi-Azizi, M | 1 |
| Torkaman-Boutorabi, A | 1 |
| Akhondzadeh, S | 1 |
| Nejatisafa, AA | 1 |
| Sadat-Shirazi, MS | 1 |
| Zarrindast, MR | 1 |
| Papp, M | 7 |
| Gruca, P | 4 |
| Lason, M | 2 |
| Tota-Glowczyk, K | 2 |
| Niemczyk, M | 2 |
| Litwa, E | 3 |
| Willner, P | 3 |
| Ashraf, NS | 1 |
| Duarte-Silva, S | 2 |
| Shaw, ED | 1 |
| Maciel, P | 2 |
| Paulson, HL | 1 |
| Teixeira-Castro, A | 2 |
| Costa, MDC | 1 |
| Zhong, Q | 1 |
| Yu, H | 1 |
| Huang, C | 1 |
| Zhong, J | 1 |
| Wang, H | 1 |
| Xu, J | 1 |
| Cheng, Y | 1 |
| Heinze, JD | 1 |
| Angelucci, F | 1 |
| Ellenbroek, BA | 1 |
| Alexander, L | 1 |
| Gaskin, PLR | 1 |
| Sawiak, SJ | 1 |
| Fryer, TD | 1 |
| Hong, YT | 1 |
| Cockcroft, GJ | 1 |
| Clarke, HF | 1 |
| Roberts, AC | 1 |
| Seo, MK | 1 |
| Lee, JG | 1 |
| Park, SW | 1 |
| Furuse, K | 1 |
| Ukai, W | 1 |
| Hashimoto, E | 1 |
| Hashiguchi, H | 1 |
| Kigawa, Y | 1 |
| Ishii, T | 1 |
| Tayama, M | 1 |
| Deriha, K | 1 |
| Shiraishi, M | 1 |
| Kawanishi, C | 1 |
| Wang, L | 2 |
| Nalvarte, I | 1 |
| Xiao, R | 1 |
| Velasquez, JC | 1 |
| Zhao, Q | 1 |
| Chan, Y | 1 |
| Galindo, LCM | 1 |
| Simasotchi, C | 1 |
| Wu, D | 2 |
| Hou, Z | 1 |
| Herod, SM | 2 |
| Oberlander, TF | 1 |
| Gil, S | 1 |
| Fournier, T | 1 |
| Burd, I | 1 |
| Andrews, AM | 2 |
| Bonnin, A | 1 |
| Sanders, BK | 1 |
| Bourke, CH | 2 |
| Capello, CF | 1 |
| Rogers, SM | 1 |
| Yu, ML | 1 |
| Boss-Williams, KA | 1 |
| Weiss, JM | 1 |
| Stowe, ZN | 2 |
| Owens, MJ | 2 |
| Huang, CC | 1 |
| Wei, IH | 1 |
| Huang, CL | 1 |
| Chen, KT | 1 |
| Tsai, MH | 1 |
| Tsai, P | 1 |
| Tun, R | 1 |
| Huang, KH | 1 |
| Chang, YC | 1 |
| Lane, HY | 1 |
| Tsai, GE | 1 |
| Yamada, M | 2 |
| Kawahara, Y | 2 |
| Kaneko, F | 2 |
| Kishikawa, Y | 1 |
| Sotogaku, N | 1 |
| Poppinga, WJ | 1 |
| Folgering, JH | 1 |
| Dremencov, E | 2 |
| Kawahara, H | 2 |
| Nishi, A | 2 |
| Rodgers, AB | 1 |
| Morgan, CP | 1 |
| Bronson, SL | 1 |
| Revello, S | 1 |
| Bale, TL | 2 |
| Wolmarans, de W | 2 |
| Brand, L | 1 |
| Stein, DJ | 7 |
| Opal, MD | 1 |
| Klenotich, SC | 1 |
| Bessa, J | 2 |
| Winkle, J | 1 |
| Doukas, D | 1 |
| Kay, LJ | 1 |
| Sousa, N | 1 |
| Dulawa, SM | 1 |
| Lotan, D | 1 |
| Einat, N | 1 |
| Yaffe, R | 1 |
| Winer, A | 1 |
| Marom, I | 1 |
| Meron, G | 1 |
| Kately, N | 1 |
| O'Brien, FE | 1 |
| O'Connor, RM | 1 |
| Clarke, G | 2 |
| Donovan, MD | 1 |
| Dinan, TG | 3 |
| Griffin, BT | 1 |
| Cryan, JF | 3 |
| Jensen, JB | 1 |
| du Jardin, KG | 1 |
| Song, D | 1 |
| Budac, D | 1 |
| Smagin, G | 1 |
| Pehrson, AL | 1 |
| Wang, SS | 1 |
| Wang, YG | 1 |
| Chen, HY | 1 |
| Wu, ZP | 1 |
| Xie, HG | 1 |
| Jin, ZL | 2 |
| Gao, N | 2 |
| Zhang, JR | 1 |
| Li, XR | 2 |
| Chen, HX | 2 |
| Xiong, J | 2 |
| Li, YF | 2 |
| Tang, Y | 2 |
| Howerton, AR | 1 |
| Roland, AV | 1 |
| Lason-Tyburkiewicz, M | 1 |
| Blom, JM | 1 |
| Gandolfi, F | 1 |
| Hache, G | 1 |
| Guiard, BP | 2 |
| Nguyen, TH | 1 |
| Quesseveur, G | 1 |
| Gardier, AM | 3 |
| Peters, D | 1 |
| Munro, G | 1 |
| Coudoré, F | 1 |
| Pardo-Peña, K | 1 |
| Medina-Ceja, L | 1 |
| Morales-Villagrán, A | 1 |
| Savignac, HM | 1 |
| Kiely, B | 2 |
| Mlyniec, K | 1 |
| Ostachowicz, B | 1 |
| Krakowska, A | 1 |
| Reczynski, W | 1 |
| Opoka, W | 1 |
| Nowak, G | 1 |
| Wang, Y | 2 |
| Chai, F | 1 |
| Liu, X | 1 |
| Berk, M | 2 |
| Altieri, SC | 1 |
| Yang, H | 1 |
| O'Brien, HJ | 1 |
| Redwine, HM | 1 |
| Senturk, D | 1 |
| Hensler, JG | 1 |
| Xue, R | 1 |
| Lin, DH | 1 |
| Zhang, XR | 1 |
| Ye, DQ | 1 |
| Xi, GJ | 2 |
| Hui, JJ | 2 |
| Liu, SS | 2 |
| Li, LJ | 1 |
| Zhang, ZJ | 9 |
| Kasahara, K | 1 |
| Hashimoto, S | 2 |
| Hattori, T | 1 |
| Kawasaki, K | 1 |
| Tsujita, R | 1 |
| Nakazono, O | 1 |
| Takao, K | 1 |
| Kawakubo, H | 1 |
| Nagatani, T | 1 |
| Zhang, Y | 1 |
| Bai, M | 1 |
| Zhang, X | 2 |
| Zhu, X | 1 |
| Zhang, GF | 1 |
| Liu, WX | 1 |
| Qiu, LL | 1 |
| Guo, J | 1 |
| Wang, XM | 1 |
| Sun, HL | 1 |
| Yang, JJ | 1 |
| Zhou, ZQ | 1 |
| Asaoka, N | 1 |
| Nagayasu, K | 1 |
| Nishitani, N | 1 |
| Yamashiro, M | 1 |
| Shirakawa, H | 1 |
| Nakagawa, T | 1 |
| Kaneko, S | 1 |
| Mokoena, ML | 1 |
| Viljoen, F | 1 |
| Ellis, SM | 1 |
| Munari, L | 1 |
| Provensi, G | 1 |
| Passani, MB | 1 |
| Galeotti, N | 2 |
| Cassano, T | 1 |
| Benetti, F | 1 |
| Corradetti, R | 1 |
| Blandina, P | 1 |
| Li, XL | 2 |
| Yuan, YG | 1 |
| Gong, WG | 2 |
| Geng, LY | 2 |
| Wu, FF | 1 |
| Tang, H | 1 |
| Xu, L | 2 |
| Fidalgo, C | 1 |
| Ko, WK | 1 |
| Tronci, E | 1 |
| Stancampiano, R | 1 |
| Chuan, Q | 1 |
| Bezard, E | 1 |
| Carta, M | 1 |
| Llamosas, N | 1 |
| Bruzos-Cidón, C | 1 |
| Rodríguez, JJ | 1 |
| Ugedo, L | 2 |
| Torrecilla, M | 1 |
| Haim, A | 1 |
| Albin-Brooks, C | 1 |
| Sherer, M | 1 |
| Mills, E | 1 |
| Leuner, B | 1 |
| Ehrlich, DE | 1 |
| Neigh, GN | 1 |
| Nemeth, CL | 1 |
| Hazra, R | 1 |
| Ryan, SJ | 1 |
| Rowson, S | 1 |
| Jairam, N | 1 |
| Sholar, CA | 1 |
| Rainnie, DG | 1 |
| Ma, L | 1 |
| Lu, ZN | 1 |
| Hu, P | 1 |
| Yao, CJ | 1 |
| Satoh, M | 1 |
| Fraher, D | 1 |
| Hodge, JM | 1 |
| Collier, FM | 1 |
| McMillan, JS | 1 |
| Kennedy, RL | 1 |
| Ellis, M | 1 |
| Nicholson, GC | 1 |
| Walder, K | 1 |
| Dodd, S | 1 |
| Pasco, JA | 1 |
| Williams, LJ | 1 |
| Gibert, Y | 1 |
| Jalles, A | 1 |
| Esteves, S | 1 |
| Kang, S | 1 |
| da Silva Santos, L | 1 |
| Silva-Fernandes, A | 1 |
| Neto, MF | 1 |
| Brielmann, RM | 1 |
| Bessa, C | 1 |
| Miranda, A | 1 |
| Oliveira, S | 1 |
| Neves-Carvalho, A | 1 |
| Summavielle, T | 1 |
| Silverman, RB | 1 |
| Oliveira, P | 1 |
| Morimoto, RI | 1 |
| Ren, QG | 1 |
| Wang, YJ | 1 |
| Nackenoff, AG | 1 |
| Moussa-Tooks, AB | 1 |
| McMeekin, AM | 1 |
| Veenstra-VanderWeele, J | 1 |
| Blakely, RD | 1 |
| Zohar, I | 1 |
| Shoham, S | 1 |
| Weinstock, M | 1 |
| Yang, SN | 1 |
| Wang, YH | 1 |
| Tung, CS | 2 |
| Ko, CY | 1 |
| Liu, YP | 2 |
| Lin, CC | 1 |
| Wolmarans, W | 1 |
| Stasiuk, W | 1 |
| Oniszczuk, A | 1 |
| Schmidt, C | 1 |
| Leibiger, J | 1 |
| Fendt, M | 1 |
| Teng, GJ | 5 |
| Nie, BB | 1 |
| Shan, BC | 1 |
| Yan, J | 1 |
| Dong, L | 1 |
| Reynolds, GP | 2 |
| Miguelez, C | 1 |
| Navailles, S | 2 |
| Delaville, C | 1 |
| Marquis, L | 1 |
| Lagière, M | 1 |
| Benazzouz, A | 1 |
| De Deurwaerdère, P | 2 |
| Fitzpatrick, CM | 1 |
| Larsen, M | 1 |
| Madsen, LH | 1 |
| Caballero-Puntiverio, M | 1 |
| Pickering, DS | 1 |
| Clausen, RP | 1 |
| Frey, A | 1 |
| Saxon, VM | 1 |
| Popp, S | 1 |
| Lehmann, M | 1 |
| Mathes, D | 1 |
| Pachel, C | 1 |
| Hofmann, U | 1 |
| Ertl, G | 1 |
| Lesch, KP | 1 |
| Frantz, S | 1 |
| Marcus, MM | 1 |
| Björkholm, C | 1 |
| Malmerfelt, A | 1 |
| Möller, A | 1 |
| Påhlsson, N | 1 |
| Konradsson-Geuken, Å | 1 |
| Feltmann, K | 1 |
| Jardemark, K | 1 |
| Schilström, B | 1 |
| Svensson, TH | 1 |
| Ibrahim, WW | 1 |
| Safar, MM | 1 |
| Khattab, MM | 1 |
| Agha, AM | 1 |
| Malki, K | 2 |
| Tosto, MG | 1 |
| Mouriño-Talín, H | 1 |
| Rodríguez-Lorenzo, S | 1 |
| Pain, O | 1 |
| Jumhaboy, I | 1 |
| Parpas, P | 1 |
| Newman, S | 1 |
| Malykh, A | 1 |
| Uher, R | 2 |
| McGuffin, P | 2 |
| Schalkwyk, LC | 2 |
| Bryson, K | 1 |
| Herbster, M | 1 |
| Sanna, MD | 1 |
| Ghelardini, C | 1 |
| Guo, K | 1 |
| Yin, G | 1 |
| Zi, XH | 1 |
| Zhu, HX | 1 |
| Pan, Q | 1 |
| Wang, SH | 5 |
| Guo, YJ | 5 |
| Zhou, H | 1 |
| Chen, BA | 4 |
| Olsen, GM | 1 |
| Wiborg, O | 10 |
| Redrobe, JP | 4 |
| Kanemaru, K | 1 |
| Hasegawa, S | 1 |
| Nishi, K | 1 |
| Diksic, M | 1 |
| Kálmán, J | 1 |
| Muraki, I | 1 |
| Koyama, T | 2 |
| Kumar, A | 1 |
| Garg, R | 1 |
| Deltheil, T | 1 |
| Tanaka, K | 1 |
| Reperant, C | 1 |
| Hen, R | 1 |
| David, DJ | 2 |
| Reed, AL | 2 |
| Anderson, JC | 1 |
| Bylund, DB | 2 |
| Petty, F | 2 |
| El Refaey, H | 1 |
| Happe, HK | 2 |
| Nagata, K | 1 |
| Imai, T | 1 |
| Yamashita, T | 1 |
| Tsuda, M | 1 |
| Tozaki-Saitoh, H | 1 |
| Inoue, K | 1 |
| Licht, CL | 1 |
| Marcussen, AB | 1 |
| Overstreet, DH | 2 |
| Aznar, S | 1 |
| Knudsen, GM | 1 |
| Tamburella, A | 1 |
| Micale, V | 1 |
| Navarria, A | 1 |
| Drago, F | 1 |
| Bjørnebekk, A | 1 |
| Brené, S | 1 |
| Pandey, DK | 1 |
| Yadav, SK | 1 |
| Mahesh, R | 1 |
| Rajkumar, R | 1 |
| Pettersen, VL | 1 |
| Zapata-Sudo, G | 1 |
| Raimundo, JM | 1 |
| Trachez, MM | 1 |
| Sudo, RT | 1 |
| Marais, L | 2 |
| Hattingh, SM | 1 |
| Daniels, WM | 2 |
| Martins-de-Souza, D | 1 |
| Harris, LW | 1 |
| Guest, PC | 1 |
| Turck, CW | 1 |
| Bahn, S | 1 |
| Mombereau, C | 1 |
| Gur, TL | 1 |
| Onksen, J | 1 |
| Blendy, JA | 1 |
| Mallei, A | 2 |
| Tardito, D | 1 |
| Gruber, SH | 3 |
| Racagni, G | 1 |
| Sui, YX | 1 |
| Sun, Y | 1 |
| Holm, MM | 1 |
| Nieto-Gonzalez, JL | 1 |
| Vardya, I | 1 |
| Henningsen, K | 1 |
| Jayatissa, MN | 5 |
| Jensen, K | 1 |
| Bioulac, B | 1 |
| Gross, C | 1 |
| Sarkisyan, G | 1 |
| Roberts, AJ | 1 |
| Hedlund, PB | 1 |
| Herrera-Pérez, JJ | 1 |
| Martínez-Mota, L | 1 |
| Fernández-Guasti, A | 2 |
| Sacre, S | 1 |
| Medghalchi, M | 1 |
| Gregory, B | 1 |
| Brennan, F | 1 |
| Williams, R | 1 |
| Romano-Torres, M | 1 |
| Sas, K | 2 |
| Becchi, S | 1 |
| Piubelli, C | 3 |
| Giambelli, R | 1 |
| Razzoli, M | 1 |
| Desbonnet, L | 1 |
| Garrett, L | 1 |
| Weissheimer, KV | 1 |
| Cameron, JL | 2 |
| Bethea, CL | 2 |
| Bhagya, V | 1 |
| Srikumar, BN | 1 |
| Raju, TR | 1 |
| Rao, BS | 1 |
| Vighini, M | 2 |
| Jiao, J | 1 |
| Nitzke, AM | 1 |
| Doukas, DG | 1 |
| Seiglie, MP | 1 |
| Dulawa, SC | 1 |
| Eriksson, TM | 1 |
| Delagrange, P | 1 |
| Spedding, M | 1 |
| Ögren, SO | 1 |
| Svenningsson, P | 2 |
| Strekalova, T | 1 |
| Couch, Y | 1 |
| Kholod, N | 1 |
| Boyks, M | 1 |
| Malin, D | 1 |
| Leprince, P | 1 |
| Steinbusch, HM | 1 |
| Bahremand, A | 1 |
| Payandemehr, B | 1 |
| Rahimian, R | 1 |
| Ziai, P | 1 |
| Pourmand, N | 1 |
| Loloee, S | 1 |
| Ebrahimi, A | 1 |
| Ghasemi, A | 1 |
| Fakhfouri, G | 1 |
| Ghasemi, M | 1 |
| Dehpour, AR | 1 |
| Furushima, Y | 1 |
| Melas, PA | 1 |
| Rogdaki, M | 1 |
| Lennartsson, A | 1 |
| Björk, K | 1 |
| Qi, H | 1 |
| Witasp, A | 1 |
| Werme, M | 1 |
| Lavebratt, C | 1 |
| Malkesman, O | 1 |
| Austin, DR | 1 |
| Tragon, T | 1 |
| Henter, ID | 1 |
| Reed, JC | 1 |
| Pellecchia, M | 1 |
| Manji, HK | 1 |
| Yilmaz, N | 1 |
| Demirdas, A | 1 |
| Yilmaz, M | 1 |
| Sutcu, R | 1 |
| Kirbas, A | 1 |
| Cure, MC | 1 |
| Eren, I | 1 |
| Bah, TM | 1 |
| Benderdour, M | 1 |
| Kaloustian, S | 1 |
| Karam, R | 1 |
| Rousseau, G | 1 |
| Godbout, R | 1 |
| Kokras, N | 1 |
| Sotiropoulos, I | 1 |
| Pitychoutis, PM | 1 |
| Almeida, OF | 1 |
| Papadopoulou-Daifoti, Z | 1 |
| Mikrouli, E | 1 |
| Wörtwein, G | 2 |
| Soylu, R | 1 |
| Petersén, Å | 2 |
| Christensen, T | 3 |
| Bisgaard, CF | 4 |
| Nielsen, EØ | 1 |
| Xi, G | 1 |
| Hui, J | 1 |
| Zhang, Z | 1 |
| Teng, G | 1 |
| Chan, KC | 1 |
| Wu, EX | 1 |
| Nie, B | 1 |
| Shan, B | 1 |
| Li, L | 1 |
| Brown, HD | 1 |
| Amodeo, DA | 1 |
| Sweeney, JA | 1 |
| Ragozzino, ME | 1 |
| Peruga, I | 1 |
| Hartwig, S | 1 |
| Merkler, D | 1 |
| Thöne, J | 1 |
| Hovemann, B | 1 |
| Juckel, G | 3 |
| Gold, R | 1 |
| Linker, RA | 1 |
| Bétry, C | 1 |
| Mnie-Filali, O | 1 |
| Etievant, A | 1 |
| Ebert, B | 1 |
| Haddjeri, N | 1 |
| Huston, JP | 2 |
| van den Brink, J | 1 |
| Komorowski, M | 2 |
| Huq, Y | 1 |
| Topic, B | 2 |
| Senashova, O | 1 |
| Vermoesen, K | 1 |
| Massie, A | 1 |
| Smolders, I | 1 |
| Clinckers, R | 1 |
| Kronenberg, G | 1 |
| Balkaya, M | 1 |
| Prinz, V | 1 |
| Gertz, K | 1 |
| Ji, S | 1 |
| Kirste, I | 1 |
| Heuser, I | 1 |
| Kampmann, B | 1 |
| Hellmann-Regen, J | 1 |
| Gass, P | 1 |
| Sohr, R | 1 |
| Hellweg, R | 1 |
| Waeber, C | 1 |
| Hörtnagl, H | 1 |
| Stumm, R | 1 |
| Endres, M | 1 |
| Lee, BS | 1 |
| Jun, IG | 1 |
| Kim, SH | 1 |
| Park, JY | 1 |
| Araya-Callís, C | 1 |
| Hiemke, C | 2 |
| Abumaria, N | 2 |
| Flugge, G | 2 |
| Nikiforuk, A | 1 |
| Ara, I | 1 |
| Bano, S | 1 |
| Klingenhegel, I | 1 |
| Paulat, J | 1 |
| Sackers, J | 1 |
| Sparkman, NL | 1 |
| Li, M | 1 |
| Dimatelis, JJ | 1 |
| Russell, VA | 1 |
| Husch, A | 1 |
| Van Patten, GN | 1 |
| Hong, DN | 1 |
| Scaperotti, MM | 1 |
| Cramer, N | 1 |
| Harris-Warrick, RM | 1 |
| Lourdusamy, A | 1 |
| Binder, E | 1 |
| Payá-Cano, J | 1 |
| Sluyter, F | 1 |
| Craig, I | 1 |
| Keers, R | 1 |
| Bak, S | 1 |
| Jensen, ON | 1 |
| Enghild, JJ | 2 |
| Toward, MA | 1 |
| Abdala, AP | 1 |
| Knopp, SJ | 1 |
| Paton, JF | 1 |
| Bissonnette, JM | 1 |
| Schaefer, TL | 1 |
| Grace, CE | 1 |
| Braun, AA | 1 |
| Amos-Kroohs, RM | 1 |
| Graham, DL | 1 |
| Skelton, MR | 1 |
| Williams, MT | 1 |
| Vorhees, CV | 1 |
| Attia, SM | 1 |
| Ashour, AE | 1 |
| Bakheet, SA | 1 |
| Takeuchi, H | 1 |
| Yatsugi, S | 1 |
| Yamaguchi, T | 1 |
| Bergqvist, PB | 1 |
| Brennum, LT | 1 |
| Gupta, S | 2 |
| Hogg, S | 3 |
| Larsen, A | 1 |
| Marcos, E | 1 |
| Adnot, S | 1 |
| Pham, MH | 1 |
| Nosjean, A | 1 |
| Raffestin, B | 1 |
| Hamon, M | 2 |
| Eddahibi, S | 1 |
| Ripoll, N | 1 |
| Dailly, E | 1 |
| Hascoët, M | 1 |
| Bourin, M | 3 |
| Fish, EW | 1 |
| Faccidomo, S | 1 |
| Miczek, KA | 2 |
| Jakus, R | 1 |
| Graf, M | 1 |
| Juhasz, G | 1 |
| Gerber, K | 1 |
| Levay, G | 1 |
| Halasz, P | 1 |
| Bagdy, G | 1 |
| Keeney, A | 1 |
| Bomholt, SF | 1 |
| Mikkelsen, JD | 1 |
| Blackburn-Munro, G | 1 |
| Neznanov, NG | 1 |
| Bortsov, AV | 1 |
| Cervo, L | 1 |
| Canetta, A | 1 |
| Calcagno, E | 1 |
| Burbassi, S | 1 |
| Sacchetti, G | 1 |
| Caccia, S | 1 |
| Fracasso, C | 1 |
| Albani, D | 1 |
| Forloni, G | 1 |
| Invernizzi, RW | 1 |
| Uys, JD | 1 |
| Muller, CJ | 1 |
| Rygula, R | 1 |
| Fuchs, E | 1 |
| Rüther, E | 1 |
| Havemann-Reinecke, U | 1 |
| Mørk, A | 1 |
| Bisgaard, C | 1 |
| Tingström, A | 1 |
| Maciag, D | 1 |
| Williams, L | 1 |
| Coppinger, D | 1 |
| Paul, IA | 1 |
| Izumi, T | 1 |
| Kitaichi, Y | 1 |
| Nakagawa, S | 1 |
| Chenu, F | 1 |
| Breuer, ME | 1 |
| Groenink, L | 1 |
| Oosting, RS | 1 |
| Westenberg, HG | 1 |
| Olivier, B | 1 |
| Jochum, T | 1 |
| Boettger, MK | 1 |
| Wigger, A | 1 |
| Beiderbeck, D | 1 |
| Neumann, ID | 1 |
| Landgraf, R | 1 |
| Sauer, H | 1 |
| Bär, KJ | 1 |
| Winter, C | 1 |
| von Rumohr, A | 1 |
| Mundt, A | 1 |
| Petrus, D | 1 |
| Klein, J | 1 |
| Lee, T | 1 |
| Morgenstern, R | 1 |
| Kupsch, A | 1 |
| Tõnissaar, M | 1 |
| Mällo, T | 1 |
| Eller, M | 1 |
| Häidkind, R | 1 |
| Kõiv, K | 1 |
| Harro, J | 1 |
| Csete, K | 1 |
| Vezekényi, Z | 1 |
| Sztriha, L | 1 |
| Vécseil, L | 1 |
| Papp, JG | 1 |
| Artemychyn, R | 1 |
| Bergström, A | 1 |
| Thykjaer, T | 1 |
| Caldwell, EE | 1 |
| Kesner, Y | 1 |
| Zohar, J | 1 |
| Merenlender, A | 1 |
| Gispan, I | 1 |
| Shalit, F | 1 |
| Yadid, G | 1 |
| West, MJ | 1 |
| Nakatomi, Y | 1 |
| Yokoyama, C | 1 |
| Kinoshita, S | 1 |
| Masaki, D | 1 |
| Tsuchida, H | 1 |
| Onoe, H | 1 |
| Yoshimoto, K | 1 |
| Fukui, K | 1 |
| Popa, D | 1 |
| Léna, C | 1 |
| Alexandre, C | 1 |
| Adrien, J | 2 |
| Kabuto, H | 1 |
| Yokoi, I | 1 |
| Endo, A | 1 |
| Takei, M | 1 |
| Kurimoto, T | 1 |
| Mori, A | 1 |
| Maudhuit, C | 1 |
| Moryl, E | 1 |
| Mendelsohn, I | 1 |
| Potocnik, F | 1 |
| Van Kradenberg, J | 1 |
| Wessels, C | 1 |
| Maurel, S | 1 |
| De Vry, J | 1 |
| Schreiber, R | 1 |
| Keeney, AJ | 1 |
| Håkanson, R | 1 |
| Nalepa, I | 1 |
| Antkiewicz-Michaluk, L | 1 |
| Kudriavtseva, NN | 1 |
| Bakshtanovskaia, IV | 1 |
| Madorskaia, IA | 1 |
| Popova, NK | 1 |
| Marona-Lewicka, D | 1 |
| Vetulani, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Examining Immune-Based Mechanisms of Action for Mild-Intensity Whole Body Hyperthermia (WBH) in the Treatment of Major Depressive Disorder[NCT03787290] | Phase 2 | 35 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | ||
| Perinatal Stress and Gene Influences: Pathways to Infant Vulnerability[NCT00525226] | 1,431 participants (Actual) | Observational | 2007-09-30 | Completed | |||
| N-methylglycine (Sarcosine) for Treatment of Major Depressive Disorder[NCT00977353] | Phase 2 | 40 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Evaluation of Efficacy and Safety of add-on Sarcosine in Patients With Major Depressive Disorder: A Randomized Controlled Trial[NCT04975100] | Phase 4 | 60 participants (Actual) | Interventional | 2021-08-26 | Completed | ||
| Clinical Study Evaluating the Efficacy of Nitazoxanide and Escitalopram as Adjuvant Therapies in Patients With Rheumatoid Arthritis[NCT05480878] | Phase 3 | 90 participants (Actual) | Interventional | 2022-12-02 | Completed | ||
| Randomized Controlled Experimental Trial Designed to Test the Effects of Probiotics on Mood[NCT03539263] | 39 participants (Actual) | Interventional | 2016-12-20 | Completed | |||
| The Safety and Effectiveness of Probiotic Supplementation on Bipolar Depression: a Proof of Concept Randomized Controlled Trial[NCT02155972] | Phase 2 | 16 participants (Actual) | Interventional | 2013-05-31 | Terminated (stopped due to The trial was terminated because of inability to recruit the needed number of participants) | ||
| "Proof-of-Concept Stress & Anxiety Dampening Effects of Lpc-37"[NCT03494725] | 120 participants (Actual) | Interventional | 2018-04-10 | Completed | |||
| A Randomized Controlled Trial of the Safety and Efficacy of Fecal Microbiota Transplantation in a Population With Bipolar Disorder[NCT03279224] | Phase 2/Phase 3 | 35 participants (Actual) | Interventional | 2018-01-01 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Efficacy of the intake of Lpc-37 on reduction of the increase of the diastolic BP in response to the TSST compared to placebo. (NCT03494725)
Timeframe: 3 minutes before the TSST and 1 minute after the TSST after 5 weeks of study product intake
| Intervention | mmHg (Mean) | |
|---|---|---|
| Pre-TSST -3min | Post-TSST +1min | |
| Lpc-37 | 79.13 | 90.38 |
| Placebo | 78.41 | 88.36 |
"Efficacy of the intake of Lpc-37 on the increase of mood scale scores over the course of the treatment~Measured with a daily online diary. Mood was rated by participants on an 11-point scale (0-10; very bad to very well) and monitored through the washout phase (week 1 and 2) and the subsequent treatment phase (weeks 3-7). Higher scores indicate a better mood. Efficacy is defined as an increase, or (in case of a general decrease) reduced decrease for the active treatment group as compared to the placebo group and operationalized as the interaction between time and treatment group. Time is coded as a continuous variable with one average value for each week and participant. Values reflect summary measures for mood ratings on a scale from 0 to 10 for the averaged ratings per participant and week." (NCT03494725)
Timeframe: Daily for 2 weeks before treatment intake and 5 weeks during treatment intake
| Intervention | score (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Week 1 (run-in) | Week 2 (run-in) | Week 3 (treatment) | Week 4 (treatment) | Week 5 (treatment) | Week 6 (treatment) | Week 7 (treatment) | |
| Lpc-37 | 7.31 | 7.53 | 7.66 | 7.77 | 7.73 | 7.90 | 7.77 |
| Placebo | 7.27 | 7.49 | 7.46 | 7.53 | 7.50 | 7.40 | 7.55 |
"Efficacy of the intake of Lpc-37 on the increase of perceived health status scores over the course of the treatment.~Measured with a daily online diary. Health status was rated by participants on an 11-point scale (0-10; not at all to very) and monitored through the wash-out phase (week 1 and 2) and the subsequent treatment phase (weeks 3-7). Higher scores indicate a high perceived health.Efficacy is defined as an increase, or (in case of a general decrease) reduced decrease for the active treatment group as compared to the placebo group and operationalized as the interaction between time and treatment group. Time is coded as a continuous variable with one value for each day and participant. Values reflect summary measures for perceived health status on a scale from 0 to 10 for the averaged ratings per participant and week." (NCT03494725)
Timeframe: Daily for 2 weeks before treatment intake and 5 weeks during treatment intake
| Intervention | score (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Week 1 (run-in) | Week 2 (run-in) | Week 3 (treatment) | Week 4 (treatment) | Week 5 (treatment) | Week 6 (treatment) | Week 7 (treatment) | |
| Lpc-37 | 7.80 | 7.89 | 7.88 | 7.91 | 8.05 | 8.11 | 7.91 |
| Placebo | 7.86 | 7.92 | 7.92 | 8.01 | 7.92 | 7.73 | 7.75 |
"Efficacy of the intake of Lpc-37 on the increase of perceived productivity scores over the course of the treatment~Measured with a daily online diary. Productivity was rated by participants on an 11-point scale (0-10; not at all to very) and monitored through the wash-out phase (week 1 and 2) and the subsequent treatment phase (weeks 3-7). Higher scores indicate a higher perceived productivity. Efficacy is defined as an increase, or (in case of a general decrease) reduced decrease for the active treatment group as compared to the placebo group and operationalized as the interaction between time and treatment group.Time is coded as a continuous variable with one value for each day and participant. The values reflect summary measures for perceived productivity on a scale from 0 to 10 for the averaged ratings per participant and week." (NCT03494725)
Timeframe: Daily for 2 weeks before treatment intake and 5 weeks during treatment intake
| Intervention | score (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Week 1 (run-in) | Week 2 (run-in) | Week 3 (treatment) | Week 4 (treatment) | Week 5 (treatment) | Week 6 (treatment) | Week 7 (treatment) | |
| Lpc-37 | 6.98 | 7.34 | 7.53 | 7.48 | 7.59 | 7.57 | 7.50 |
| Placebo | 7.15 | 7.29 | 7.30 | 7.34 | 7.43 | 7.31 | 7.32 |
"Efficacy of the intake of Lpc-37 on the decrease of reported number of sleep disruptions over the course of the treatment measured with a daily online diary (mean of week summary).~Sleep disruptions were monitored through the wash-out phase (Week 1 and 2) and the subsequent treatment phase (Weeks 3-7). In the count version, the value can be 0 or a natural number for each day and each participant. Efficacy is defined as a decrease, or (in case of a general increase) reduced increase for the active treatment group as compared to the placebo group and operationalized as the interaction between time and treatment group. Time is coded as a continuous variable with one value for each day and participant. Values reflect summary measures for sleep disruptions (count) for the summed counts per participant and week." (NCT03494725)
Timeframe: Daily for 2 weeks before treatment intake and 5 weeks during treatment intake
| Intervention | sleep disruptions per participant & week (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Week 1 (run-in) | Week 2 (run-in) | Week 3 (treatment) | Week 4 (treatment) | Week 5 (treatment) | Week 6 (treatment) | Week 7 (treatment) | |
| Lpc-37 | 7.30 | 5.50 | 4.89 | 5.43 | 3.52 | 3.80 | 4.66 |
| Placebo | 6.09 | 5.49 | 5.11 | 4.30 | 3.53 | 4.02 | 5.83 |
"Efficacy of the intake of Lpc-37 on the decrease of sleep disruptions over the course of the treatment measured with a daily online diary (Proportion (yes/total)).~Sleep disruptions were monitored through the wash-out phase and the subsequent treatment phase for each week. In the binary version, the value is either Yes or No for each day and each participant.~Efficacy is defined as a decrease, or (in case of a general increase) reduced increase for the active treatment group as compared to the placebo group and operationalized as the interaction between time and treatment group. Time is coded as a continuous variable with one value for each day and participant.~The proportion of participants with at least one sleep disruption by treatment group is given, treatment commenced after week 2. Data listed here reflect the proportion of participants who answered Yes (e.g. 0,477 * 44 = 20.99 participants answered with Yes in week 1 in the Lpc-37 group)." (NCT03494725)
Timeframe: Daily for 2 weeks before treatment intake and 5 weeks during treatment intake
| Intervention | Proportion of participants (yes/total) (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Week 1 (run-in) | Week 2 (run-in) | Week 3 (treatment) | Week 4 (treatment) | Week 5 (treatment) | Week 6 (treatment) | Week 7 (treatment) | |
| Lpc-37 | 0.477 | 0.435 | 0.354 | 0.367 | 0.306 | 0.279 | 0.290 |
| Placebo | 0.465 | 0.426 | 0.418 | 0.310 | 0.292 | 0.331 | 0.389 |
Efficacy of the intake of Lpc-37 on reduction of the increase of salivary Alpha-Amylase (sAA) in response to the TSST compared to placebo. (NCT03494725)
Timeframe: 1 minute before the TSST and 1, 10, 20, 30 and 45 minutes after the TSST after 5 weeks of study product intake
| Intervention | U/ml (Mean) | |||||
|---|---|---|---|---|---|---|
| Pre-TSST -2min | Post-TSST +1min | Post-TSST +10min | Post-TSST +20min | Post-TSST +30min | Post-TSST +45min | |
| Lpc-37 | 154.04 | 246.29 | 146.53 | 130.11 | 125.19 | 141.13 |
| Placebo | 161.67 | 270.55 | 158.85 | 141.49 | 138.48 | 148.15 |
Efficacy of the intake of Lpc-37 on reduction of the increase of salivary cortisol in response to the TSST compared to placebo. (NCT03494725)
Timeframe: 1 minute before the TSST and 1, 10, 20, 30 and 45 minutes after the TSST after 5 weeks of study product intake
| Intervention | nmol/L (Mean) | |||||
|---|---|---|---|---|---|---|
| Pre-TSST -2min | Post-TSST +1min | Post-TSST +10min | Post-TSST +20min | Post-TSST +30min | Post-TSST +45min | |
| Lpc-37 | 4.79 | 6.96 | 9.48 | 9.89 | 8.04 | 6.21 |
| Placebo | 4.82 | 6.85 | 8.97 | 9.21 | 7.71 | 6.16 |
"Efficacy of the intake of Lpc-37 on the increase of sleep duration over the course of the treatment.~Sleep duration was monitored through the wash-out phase (week 1 and 2) and the subsequent treatment phase (weeks 3-7). Efficacy is defined as an increase, or (in case of a general decrease) reduced decrease for the active treatment group as compared to the placebo group and operationalized as the interaction between time and treatment group. Time is coded as a continuous variable with one value for each day and participant. Summary measures for Sleep duration for the averaged ratings per participant and week" (NCT03494725)
Timeframe: Daily for 2 weeks before treatment intake and 5 weeks during treatment intake
| Intervention | min (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Week 1 (run-in) | Week 2 (run-in) | Week 3 (treatment) | Week 4 (treatment) | Week 5 (treatment) | Week 6 (treatment) | Week 7 (treatment) | |
| Lpc-37 | 447.27 | 444.01 | 449.45 | 450.62 | 454.50 | 450.88 | 445.60 |
| Placebo | 447.45 | 448.13 | 456.90 | 459.81 | 457.26 | 450.16 | 459.66 |
"Efficacy of the intake of Lpc-37 on the increase of sleep related recovery scores over the course of the treatment.~Measured with a daily online diary. Sleep related recovery was rated by participants on an 11-point scale (0-10; not at all to very) and monitored throughout the wash-out phase (Week 1 and 2) and the subsequent treatment phase (weeks 3-7). High scores indicate a high recovery.~Efficacy is defined as an increase, or (in case of a general decrease) reduced decrease for the active treatment group as compared to the placebo group and operationalized as the interaction between time and treatment group. Time is coded as a continuous variable with one value for each day and participant. Summary measures for sleep related recovery for the averaged ratings per participant and week." (NCT03494725)
Timeframe: Daily for 2 weeks before treatment intake and 5 weeks during treatment intake
| Intervention | score (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Week 1 (run-in) | Week 2 (run-in) | Week 3 (treatment) | Week 4 (treatment) | Week 5 (treatment) | Week 6 (treatment) | Week 7 (treatment) | |
| Lpc-37 | 6.71 | 7.07 | 7.32 | 7.30 | 7.36 | 7.42 | 7.31 |
| Placebo | 6.91 | 7.15 | 7.27 | 7.29 | 7.36 | 7.10 | 7.28 |
"Efficacy of the intake of Lpc-37 on reduction of the increase of STAI-State scores in response to the TSST compared to placebo.~Measured with the german version of the State-Trait-Anxiety Inventory, scale anxiety as a temporary emotional state (STAI-X1). Answers are given on a four-point rating scale ranging from 1=not at all to 4=very true. The score range is 20-80; Higher scores indicate more anxiety." (NCT03494725)
Timeframe: 10 minutes before the TSST and 1 minute after the TSST after 5 weeks of study product intake
| Intervention | score (Mean) | |
|---|---|---|
| Pre-TSST -10min | Post-TSST +1min | |
| Lpc-37 | 36.09 | 42.38 |
| Placebo | 36.83 | 43.60 |
Efficacy of the intake of Lpc-37 on reduction of the increase of the systolic BP in response to the TSST compared to placebo. (NCT03494725)
Timeframe: 3 minutes before the TSST and 1 minute after the TSST after 5 weeks of study product intake
| Intervention | mmHg (Mean) | |
|---|---|---|
| Pre-TSST -3min | Post-TSST +1min | |
| Lpc-37 | 115.11 | 127.47 |
| Placebo | 114.33 | 129.19 |
Efficacy was defined as a lower increase in HR in response to the TSST following intervention with Lpc-37, compared to placebo. (NCT03494725)
Timeframe: Continuous measurement starting 20 minutes before and ending 20 minutes after the TSST after 5 weeks of product intake. Mean values were calculated per group at seven-time windows before, during and after the TSST
| Intervention | bpm (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Pre-TSST -20min | Pre-TSST -10min | Pre-TSST -3min | during TSST (Interview) | during TSST (Arithmetic) | Post-TSST +10min | Post-TSST +20min | |
| Lpc-37 | 74.84 | 88.15 | 97.34 | 107.56 | 102.77 | 93.32 | 75.88 |
| Placebo | 74.34 | 86.69 | 97.62 | 105.66 | 100.81 | 90.81 | 74.97 |
"Efficacy of the intake of Lpc-37 on reduction of the increase of VAS anxiety scores in response to the TSST compared to placebo.~Measured with a german version of the Visual Analog Scale (VAS) as a 10cm bipolar scale ranging from not at all to highly. The participant indicated his/her actual perception by placing a mark on a line. VAS scores were obtained by using a ruler and measuring the position of the participants's mark with millimeter precision. To control for possible variations due to printing, the total length of the line was also measured and percentage scores for each participant were computed. Percentage scores range from 0-100. Higher scores indicating greater anxiety." (NCT03494725)
Timeframe: 10 minutes before the TSST, during the TSST and 1 minute after the TSST after 5 weeks of study product intake
| Intervention | score (Mean) | ||
|---|---|---|---|
| Pre-TSST -10min | Interview TSST (during) | Post-TSST +1min | |
| Lpc-37 | 6.80 | 20.85 | 10.68 |
| Placebo | 8.50 | 22.47 | 11.74 |
"Efficacy of the intake of Lpc-37 on reduction of the increase of VAS exhaustion scores in response to the TSST compared to placebo.~Measured with a german version of the Visual Analog Scale (VAS) as a 10cm bipolar scale ranging from not at all to highly. The participant indicated his/her actual perception by placing a mark on a line. VAS scores were obtained by using a ruler and measuring the position of the participants's mark with millimeter precision. To control for possible variations due to printing, the total length of the line was also measured and percentage scores for each participant were computed. Percentage scores range from 0-100. Higher scores indicating greater exhaustion." (NCT03494725)
Timeframe: 10 minutes before the TSST, during the TSST and 1 minute after the TSST after 5 weeks of study product intake
| Intervention | score (Mean) | ||
|---|---|---|---|
| Pre-TSST -10min | Interview TSST (during) | Post-TSST +1min | |
| Lpc-37 | 21.18 | 19.20 | 22.12 |
| Placebo | 19.79 | 21.30 | 25.68 |
"Efficacy of the intake of Lpc-37 on reduction of the increase of VAS insecurity scores in response to the TSST compared to placebo.~Measured with a german version of the Visual Analog Scale (VAS) as a 10cm bipolar scale ranging from not at all to highly. The participant indicated his/her actual perception by placing a mark on a line. VAS scores were obtained by using a ruler and measuring the position of the participants's mark with millimeter precision. To control for possible variations due to printing, the total length of the line was also measured and percentage scores for each participant were computed. Percentage scores range from 0-100. Higher scores indicating greater insecurity." (NCT03494725)
Timeframe: 10 minutes before the TSST, during the TSST and 1 minute after the TSST after 5 weeks of study product intake
| Intervention | score (Mean) | ||
|---|---|---|---|
| Pre-TSST -10min | Interview TSST (during) | Post-TSST +1min | |
| Lpc-37 | 14.47 | 45.08 | 23.92 |
| Placebo | 17.19 | 52.19 | 23.69 |
"Efficacy of the intake of Lpc-37 on reduction of the increase of VAS Stress perception scores in response to the TSST compared to placebo.~Measured with a german version of the Visual Analog Scale (VAS) as a 10cm bipolar scale ranging from not at all to highly. The participant indicated his/her actual perception by placing a mark on a line. VAS scores were obtained by using a ruler and measuring the position of the participants's mark with millimeter precision. To control for possible variations due to printing, the total length of the line was also measured and percentage scores for each participant were computed. Percentage scores range from 0-100. Higher scores indicating higher perceived stress." (NCT03494725)
Timeframe: 10 minutes before the TSST, during the TSST and 1 minute after the TSST after 5 weeks of study product intake
| Intervention | score (Mean) | ||
|---|---|---|---|
| Pre-TSST -10min | Interview TSST (during) | Post-TSST +1min | |
| Lpc-37 | 19.89 | 47.71 | 31.72 |
| Placebo | 18.52 | 51.51 | 32.85 |
"Efficacy of the intake of Lpc-37 on the reduction of Beck Anxiety Inventory (BAI) scores compared to placebo.~Measured with the german version of the Beck Anxiety Inventory as a self-rating scale designed to measure anxiety. It comprises 21 sentences describing feelings that can occur when being anxious. These sentences are rated on a four-point rating scale ranging from 0=not at all to 3=severely, considering the last 7 days. The score range is 0-63; Higher scores indicate higher anxiety." (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | score (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 5.51 | 4.75 |
| Placebo | 5.85 | 6.33 |
"Efficacy of the intake of Lpc-37 on the reduction of Depression Anxiety Stress Scale (DASS) anxiety scores compared to placebo.~Measured with the german version of the DASS as a 42-item self report instrument designed to measure negative emotional states of depression, anxiety and stress during the past week. The DASS includes three scales (depression, anxiety and stress) of which each scale includes 14 items that are divided into subscales of 2-5 items of similar content.~Items are answered on a four point rating scale ranging from 0 = not at all to 3 = very much. Scores of each scale are calculated by summing the scores for the relevant items.~The anxiety scale assesses autonomic arousal, skeletal muscle effects, situational anxiety, and subjective experience of anxious affect. The items are 2, 4, 7, 9, 15, 19, 20, 23, 25, 28, 30, 36, 40, 41 and individual scores can range from 0 to 42 with higher scores indicating greater severity of the symptoms." (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | score (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 2.60 | 2.44 |
| Placebo | 3.07 | 3.45 |
"Efficacy of the intake of Lpc-37 on the reduction of Depression Anxiety Stress Scale (DASS) depression scores compared to placebo.~Measured with the german version of the DASS as a 42-item self report instrument designed to measure negative emotional states of depression, anxiety and stress during the past week. The DASS includes three scales (depression, anxiety and stress) of which each scale includes 14 items that are divided into subscales of 2-5 items of similar content.~Items are answered on a four point rating scale ranging from 0 = not at all to 3 = very much. Scores of each scale are calculated by summing the scores for the relevant items.~The Depression scale assesses dysphoria, hopelessness, devaluation of life, self-deprecation, lack of interest/involvement, anhedonia, and inertia. The items are 3, 5, 10, 13, 16, 17, 21, 24, 26, 31, 34, 37, 38, 42 and individual scores can range from 0 to 42 with higher scores indicating greater severity of the symptoms." (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | score (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 4.60 | 4.15 |
| Placebo | 5.21 | 5.10 |
"Efficacy of the intake of Lpc-37 on the reduction of Depression Anxiety Stress Scale (DASS) stress scores compared to placebo.~Measured with the german version of the DASS as a 42-item self report instrument designed to measure negative emotional states of depression, anxiety and stress during the past week. The DASS includes three scales (depression, anxiety and stress) of which each scale includes 14 items that are divided into subscales of 2-5 items of similar content.~Items are answered on a four point rating scale ranging from 0 = not at all to 3 = very much. Scores of each scale are calculated by summing the scores for the relevant items.~The stress scale (items) is sensitive to levels of chronic non-specific arousal.The stress scale items are 1, 6, 8, 11, 12, 14, 18, 22, 27, 29, 32, 33, 35, 39 and individual scores can range from 0 to 42 with higher scores indicating greater severity of the symptoms." (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | score (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 9.76 | 8.91 |
| Placebo | 9.41 | 10.09 |
Efficacy of the intake of Lpc-37 on the reduction of diastolic BP. (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | mmHg (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 71.89 | 73.18 |
| Placebo | 71.68 | 74.62 |
"Efficacy of the intake of Lpc-37 on the reduction of Perceived Stress Scale (PSS) scores compared to placebo.~Measured with the german version of the PSS as a psychological instrument for measuring stress perception. It assesses how unpredictable, uncontrollable and overloaded participants perceived their lives to have been within the last month. The PSS comprises 14 items that are answered on a five-point rating scale ranging from 0 = never to 4 = very often. Individual scores on the PSS can range from 0 to 56 with higher scores indicating higher perceived stress." (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | score (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 21.89 | 20.49 |
| Placebo | 20.72 | 21.56 |
"Efficacy of the intake of Lpc-37 on the reduction of State-Trait-Anxiety-Inventory (STAI)-state scores compared to placebo.~Measured with the german version of the State-Trait-Anxiety Inventory, scale anxiety as a temporary emotional state (STAI-X1). Answers are given on a four-point rating scale ranging from 1=not at all to 4=very true. The score range is 20-80; Higher scores indicate more anxiety." (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | score (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 33.65 | 35.18 |
| Placebo | 34.33 | 35.33 |
Efficacy of the intake of Lpc-37 on the reduction of systolic blood pressure (BP). (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | mmHg (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 119.60 | 121.87 |
| Placebo | 119.66 | 122.86 |
"Efficacy of the intake of Lpc-37 on the reduction of VAS anxiety scores compared to placebo.~Measured with a german version of the Visual Analog Scale (VAS) as a 10cm bipolar scale ranging from not at all to highly. The participant indicated his/her actual perception by placing a mark on a line. VAS scores were obtained by using a ruler and measuring the position of the participants's mark with millimeter precision. To control for possible variations due to printing, the total length of the line was also measured and percentage scores for each participant were computed. Percentage scores range from 0-100. Higher scores indicating greater anxiety." (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | score (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 7.29 | 9.26 |
| Placebo | 7.58 | 7.85 |
"Efficacy of the intake of Lpc-37 on the reduction of VAS exhaustion scores compared to placebo.~Measured with a german version of the Visual Analog Scale (VAS) as a 10cm bipolar scale ranging from not at all to highly. The participant indicated his/her actual perception by placing a mark on a line. VAS scores were obtained by using a ruler and measuring the position of the participants's mark with millimeter precision. To control for possible variations due to printing, the total length of the line was also measured and percentage scores for each participant were computed. Percentage scores range from 0-100. Higher scores indicating greater exhaustion." (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | score (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 29.56 | 24.66 |
| Placebo | 23.19 | 18.45 |
"Efficacy of the intake of Lpc-37 on the reduction of VAS insecurity scores compared to placebo.~Measured with a german version of the Visual Analog Scale (VAS) as a 10cm bipolar scale ranging from not at all to highly. The participant indicated his/her actual perception by placing a mark on a line. VAS scores were obtained by using a ruler and measuring the position of the participants's mark with millimeter precision. To control for possible variations due to printing, the total length of the line was also measured and percentage scores for each participant were computed. Percentage scores range from 0-100. Higher scores indicating greater insecurity." (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | score (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 13.58 | 16.44 |
| Placebo | 15.91 | 17.30 |
"Efficacy of the intake of Lpc-37 on the reduction of Visual Analog Scale (VAS) stress perception scores compared to placebo.~Measured with a german version of the Visual Analog Scale (VAS) as a 10cm bipolar scale ranging from not at all to highly. The participant indicated his/her actual perception by placing a mark on a line. VAS scores were obtained by using a ruler and measuring the position of the participants's mark with millimeter precision. To control for possible variations due to printing, the total length of the line was also measured and percentage scores for each participant were computed. Percentage scores range from 0-100. Higher scores indicating higher perceived stress." (NCT03494725)
Timeframe: Before and after 5 weeks of study product intake.
| Intervention | score (Mean) | |
|---|---|---|
| Baseline | End of Study | |
| Lpc-37 | 19.11 | 23.32 |
| Placebo | 19.34 | 20.67 |
"Efficacy of the intake of Lpc-37 on the reduction of the difference of cortisol at 8 pm values to the respective mean before and after 5 weeks of treatment~Efficacy for the CAR variable cortisol at 8 pm is defined in terms of a normalization: Number of participants with normal values (between first and third quantile of reference measures) and numbers of participants with low or high values are compared before treatment and after treatment. More participants in the normal range after treatment is defined as efficacy." (NCT03494725)
Timeframe: Baseline (average of 2 days before first product intake) and end of study (average of 2 days before last product intake
| Intervention | number of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Baseline (<25% quantile) | Baseline (25% - 75% quantile) | Baseline (>75% quantile) | End of Study (<25% quantile) | End of Study (25% - 75% quantile) | End of Study (>75% quantile) | |
| Lpc-37 | 4 | 20 | 29 | 3 | 28 | 22 |
| Placebo | 6 | 23 | 26 | 7 | 18 | 30 |
"Efficacy of the intake of Lpc-37 on the reduction of the difference of Cortisol Awakening Response (CAR) area under the curve with respect to the ground (AUCg) values to the respective mean before and after 5 weeks of treatment.~The CAR is summarized in the variables AUCg, AUCi, mean increase and peak value. These cortisol indices are frequently used to describe hypothalamic-pituitary-adrenal axis activity and represent information either of the total cortisol production or of the change in cortisol levels. AUCg is the total area under the curve of all measurements (i.e., the intensity or magnitude of the response).~Efficacy for the CAR variables AUCg is defined in terms of a normalization: Number of participants with normal values (between first and third quantile of reference measures) and numbers of participants with low or high values are compared before treatment and after treatment. More participants in the normal range after treatment is defined as efficacy." (NCT03494725)
Timeframe: Baseline (average of 2 days before first product intake) and end of study (average of 2 days before last product intake)
| Intervention | number of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Baseline (<25% quantile) | Baseline (25% - 75% quantile) | Baseline (>75% quantile) | End of Study (<25% quantile) | End of Study (25% - 75% quantile) | End of Study (>75% quantile) | |
| Lpc-37 | 6 | 36 | 11 | 11 | 28 | 14 |
| Placebo | 12 | 30 | 13 | 7 | 35 | 13 |
"Efficacy of the intake of Lpc-37 on the reduction of the difference of Cortisol at Awakening values to the respective mean before and after 5 weeks of treatment~Efficacy for the CAR variable cortisol at awakening is defined in terms of a normalization: Number of participants with normal values (between first and third quantile of reference measures) and numbers of participants with low or high values are compared before treatment and after treatment. More participants in the normal range after treatment is defined as efficacy." (NCT03494725)
Timeframe: Baseline (average of 2 days before first product intake) and end of study (average of 2 days before last product intake)
| Intervention | number of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Baseline (<25% quantile) | Baseline (25% - 75% quantile) | Baseline (>75% quantile) | End of Study (<25% quantile) | End of Study (25% - 75% quantile) | End of Study (>75% quantile) | |
| Lpc-37 | 14 | 31 | 8 | 19 | 26 | 8 |
| Placebo | 16 | 26 | 13 | 12 | 34 | 9 |
"Efficacy of the intake of Lpc-37 on the reduction of the difference of CAR area under the curve with respect to the increase (AUCi) values to the respective mean before and after the treatment.~The CAR is summarized in the variables AUCg, AUCi, mean increase and peak value. These cortisol indices are frequently used to describe hypothalamic-pituitary-adrenal axis activity and represent information either of the total cortisol production or of the change in cortisol levels. AUCi is calculated with reference to the baseline measurement and it ignores the distance from zero for all measurements and emphasizes the changes over time. Efficacy for the CAR variables AUCi is defined in terms of a normalization: Number of participants with normal values (between first and third quantile of reference measures) and numbers of participants with low or high values are compared before treatment and after treatment. More participants in the normal range after treatment is defined as efficacy." (NCT03494725)
Timeframe: Baseline (average of 2 days before first product intake) and end of study (average of 2 days before last product intake)
| Intervention | number of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Baseline (<25% quantile) | Baseline (25% - 75% quantile) | Baseline (>75% quantile) | End of Study (<25% quantile) | End of Study (25% - 75% quantile) | End of Study (>75% quantile) | |
| Lpc-37 | 16 | 34 | 3 | 15 | 34 | 4 |
| Placebo | 22 | 28 | 5 | 15 | 36 | 4 |
4 reviews available for citalopram and Disease Models, Animal
| Article | Year |
|---|---|
Flowers for Algernon: steroid dysgenesis, epigenetics and brain disorders.
Topics: Animals; Brain; Child; Child Development Disorders, Pervasive; Citalopram; Disease Models, Animal; E | 2012 |
[Genomical and metabolomical abnormalities in Alzheimer disease and in experimental models].
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Antidepressive Agents; Apolipoprotein E4 | 2008 |
Update in the methodology of the chronic stress paradigm: internal control matters.
Topics: Animals; Citalopram; Control Groups; Disease Models, Animal; Drinking; Food Preferences; Gene Expres | 2011 |
[A new quality of the therapy of anxiety and depression--escitalopram].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antidepressive Agents, Second-Generation; Anxie | 2005 |
2 trials available for citalopram and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression.
Topics: Adult; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depress | 2013 |
Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression.
Topics: Adult; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depress | 2013 |
Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression.
Topics: Adult; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depress | 2013 |
Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression.
Topics: Adult; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depress | 2013 |
Paternal stress exposure alters sperm microRNA content and reprograms offspring HPA stress axis regulation.
Topics: Acoustic Stimulation; Adaptation, Ocular; Analysis of Variance; Animals; Animals, Newborn; Citalopra | 2013 |
212 other studies available for citalopram and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Delayed citalopram administration reduces brain inflammation and enhances skilled motor function after ischaemic stroke in 'MacGreen' mice.
Topics: Animals; Brain Ischemia; Citalopram; Disease Models, Animal; Encephalitis; Ischemic Stroke; Mice; Ne | 2022 |
Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization.
Topics: Anhedonia; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Citalopram; Depressive | 2022 |
Partial resistance to citalopram in a Wistar-Kyoto rat model of depression: An evaluation using resting-state functional MRI and graph analysis.
Topics: Animals; Citalopram; Depression; Depressive Disorder, Treatment-Resistant; Disease Models, Animal; H | 2022 |
Effects of Escitalopram on the Functional Neural Circuits in an Animal Model of Adolescent Depression.
Topics: Animals; Citalopram; Depression; Disease Models, Animal; Escitalopram; gamma-Aminobutyric Acid; Glut | 2023 |
Attenuation of auditory mismatch negativity in serotonin transporter knockout mice with anxiety-related behaviors.
Topics: Animals; Anxiety; Auditory Cortex; Behavior, Animal; Citalopram; Disease Models, Animal; Evoked Pote | 2020 |
Dopaminergic and serotonergic modulation of social reward appraisal in zebrafish (Danio rerio) under circumstances of motivational conflict: Towards a screening test for anti-compulsive drug action.
Topics: Animals; Apomorphine; Behavior, Animal; Citalopram; Conflict, Psychological; Disease Models, Animal; | 2020 |
Gene expression signature of antidepressant treatment response/non-response in Flinders Sensitive Line rats subjected to maternal separation.
Topics: Animals; Antidepressive Agents; Citalopram; Depressive Disorder, Treatment-Resistant; Disease Models | 2020 |
Folic acid ameliorates depression-like behaviour in a rat model of chronic unpredictable mild stress.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Behavior, Animal; Biogenic | 2020 |
Citalopram Administration Does Not Promote Function or Histological Recovery after Spinal Cord Injury.
Topics: Animals; Citalopram; Disease Models, Animal; Female; Rats; Rats, Wistar; Recovery of Function; Selec | 2020 |
Depression-Associated Gene
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents, Tricyclic; Cell Adhesion Molecules, Ne | 2020 |
Effect of escitalopram on Aβ levels and plaque load in an Alzheimer mouse model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Citalopram | 2020 |
Investigating the role of 5-HT2A and 5-HT2C receptor activation in the effects of psilocybin, DOI, and citalopram on marble burying in mice.
Topics: Aminopyridines; Amphetamines; Animals; Behavior, Animal; Citalopram; Compulsive Behavior; Disease Mo | 2021 |
Protective effects of antidepressant citalopram against abnormal APP processing and amyloid beta-induced mitochondrial dynamics, biogenesis, mitophagy and synaptic toxicities in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Autophagy; Citalo | 2021 |
Selective serotonin reuptake inhibitor citalopram ameliorates cognitive decline and protects against amyloid beta-induced mitochondrial dynamics, biogenesis, autophagy, mitophagy and synaptic toxicities in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Autophagy; Citalo | 2021 |
Synergy of oxytocin and citalopram in modulating Itgb3/Chl1 interplay: Relevance to sensitivity to SSRI therapy.
Topics: Animals; Antidepressive Agents; Anxiety; Cell Adhesion Molecules; Citalopram; Corticosterone; Depres | 2021 |
Moderation of the transgenerational transference of antenatal stress-induced anxiety.
Topics: Animals; Anxiety; Citalopram; COVID-19; Crataegus; Disease Models, Animal; Drugs, Chinese Herbal; Fe | 2021 |
A combined therapeutic regimen of citalopram and environmental enrichment ameliorates attentional set-shifting performance after brain trauma.
Topics: Animals; Attention; Behavior, Animal; Brain Injuries, Traumatic; Citalopram; Cognitive Dysfunction; | 2021 |
Escitalopram Targets Oxidative Stress, Caspase-3, BDNF and MeCP2 in the Hippocampus and Frontal Cortex of a Rat Model of Depression Induced by Chronic Unpredictable Mild Stress.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Brain-Derived Neurotrophic Fact | 2021 |
Suppression of reward-induced dopamine release in the nucleus accumbens in animal models of depression: Differential responses to drug treatment.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Disease Models, Animal; Dopamine; Inhibition | 2017 |
Whole-body hyperthermia and a subthreshold dose of citalopram act synergistically to induce antidepressant-like behavioral responses in adolescent rats.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Body Temperature; Body Weight; Citalopram; Dep | 2017 |
The involvement of monoaminergic neurotransmission in the antidepressant-like action of scopolamine in the tail suspension test.
Topics: alpha-Methyltyrosine; Animals; Antidepressive Agents; Citalopram; Depressive Disorder; Disease Model | 2017 |
Effects of escitalopram and imipramine on cocaine reinforcement and drug-seeking behaviors in a rat model of depression.
Topics: Animals; Citalopram; Cocaine; Cocaine-Related Disorders; Cues; Depressive Disorder; Disease Models, | 2017 |
Differential effects of neonatal SSRI treatments on hypoxia-induced behavioral changes in male and female offspring.
Topics: Animals; Animals, Newborn; Behavior, Animal; Citalopram; Disease Models, Animal; Female; Fluoxetine; | 2017 |
Biphasic effects of selective serotonin reuptake inhibitors on anxiety: rapid reversal of escitalopram's anxiogenic effects in the novelty-induced hypophagia test in mice?
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Anxiety Disorders; Behavior, Animal; C | 2018 |
Molecular changes associated with escitalopram response in a stress-based model of depression.
Topics: Adrenocorticotropic Hormone; Animals; Antidepressive Agents; Citalopram; Corticosterone; Corticotrop | 2018 |
Chronic treatment with caffeine and its withdrawal modify the antidepressant-like activity of selective serotonin reuptake inhibitors in the forced swim and tail suspension tests in mice. Effects on Comt, Slc6a15 and Adora1 gene expression.
Topics: Amino Acid Transport Systems, Neutral; Animals; Antidepressive Agents, Second-Generation; Behavior, | 2017 |
Escitalopram and NHT normalized stress-induced anhedonia and molecular neuroadaptations in a mouse model of depression.
Topics: Anhedonia; Animals; Antidepressive Agents, Second-Generation; Brain-Derived Neurotrophic Factor; Cit | 2017 |
Marble burying as compulsive behaviors in male and female mice.
Topics: Analysis of Variance; Animals; Anti-Anxiety Agents; Behavior, Animal; Citalopram; Compulsive Behavio | 2017 |
Citalopram restores short-term memory deficit and non-cognitive behaviors in APP/PS1 mice while halting the advance of Alzheimer's disease-like pathology.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cerebral Cortex; | 2018 |
Effects of Xiao Yao San on interferon-α-induced depression in mice.
Topics: Animals; Antidepressive Agents; Calcium-Binding Proteins; Citalopram; Depression; Disease Models, An | 2018 |
P11 promoter methylation predicts the antidepressant effect of electroconvulsive therapy.
Topics: Adult; Aged; Animals; Antidepressive Agents; Biomarkers; Cell-Penetrating Peptides; Citalopram; Depr | 2018 |
Serotonin 5-HT
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Disease Models, Animal; Dose-Response Relati | 2018 |
Immediate and long-term antidepressive-like effects of pre-pubertal escitalopram and omega-3 supplementation combination in young adult stress-sensitive rats.
Topics: Animals; Antidepressive Agents; Citalopram; Depressive Disorder; Dietary Supplements; Disease Models | 2018 |
Sex-dependent behavior, neuropeptide profile and antidepressant response in rat model of depression.
Topics: Animals; Antidepressive Agents, Second-Generation; Brain; Brain Edema; Citalopram; Depressive Disord | 2018 |
Combined treatment with aripiprazole and antidepressants reversed some MK-801-induced schizophrenia-like symptoms in mice.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Disease Models, Anim | 2018 |
Differential effects of citalopram on sleep-deprivation-induced depressive-like behavior and memory impairments in mice.
Topics: Animals; Antidepressive Agents, Second-Generation; Citalopram; CREB-Binding Protein; Depression; Dis | 2019 |
Influence of citicoline on citalopram-induced antidepressant activity in depressive-like symptoms in male mice.
Topics: Animals; Antidepressive Agents; Chemotherapy, Adjuvant; Citalopram; Cytidine Diphosphate Choline; De | 2018 |
Rapid antidepressant effects of deep brain stimulation of the pre-frontal cortex in an animal model of treatment-resistant depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Deep Brain Stimulation; Depressive Dis | 2018 |
Citalopram Reduces Aggregation of ATXN3 in a YAC Transgenic Mouse Model of Machado-Joseph Disease.
Topics: Animals; Ataxin-3; Autophagy; Brain; Citalopram; Disease Models, Animal; Inclusion Bodies; Machado-J | 2019 |
Validation of chronic mild stress in the Wistar-Kyoto rat as an animal model of treatment-resistant depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depression; Depressive Disorder; Depre | 2019 |
FCPR16, a novel phosphodiesterase 4 inhibitor, produces an antidepressant-like effect in mice exposed to chronic unpredictable mild stress.
Topics: Animals; Antidepressive Agents; Benzamides; Cerebral Cortex; Chronic Disease; Citalopram; Cyclic AMP | 2019 |
Interactions between whole-body heating and citalopram on body temperature, antidepressant-like behaviour, and neurochemistry in adolescent male rats.
Topics: Animals; Antidepressive Agents; Body Temperature; Citalopram; Combined Modality Therapy; Depressive | 2019 |
CGRP in a gene-environment interaction model for depression: effects of antidepressant treatment.
Topics: Amygdala; Animals; Antidepressive Agents; Brain; Calcitonin Gene-Related Peptide; Citalopram; Depres | 2019 |
Fractionating Blunted Reward Processing Characteristic of Anhedonia by Over-Activating Primate Subgenual Anterior Cingulate Cortex.
Topics: Anhedonia; Animals; Blood Pressure; Callithrix; Citalopram; Conditioning, Classical; Discrimination, | 2019 |
Effects of escitalopram and ibuprofen on a depression-like phenotype induced by chronic stress in rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Citalopram; Cor | 2019 |
Antidepressant activities of escitalopram and blonanserin on prenatal and adolescent combined stress-induced depression model: Possible role of neurotrophic mechanism change in serum and nucleus accumbens.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Citalopram; Cor | 2019 |
Citalopram attenuates social behavior deficits in the BTBR T
Topics: Animals; Autism Spectrum Disorder; Behavior, Animal; Citalopram; Disease Models, Animal; Grooming; M | 2019 |
Topics: Animals; Brain; Citalopram; Disease Models, Animal; Female; Fetal Development; Magnetic Resonance Im | 2019 |
Prenatal exposure to escitalopram and/or stress in rats: a prenatal stress model of maternal depression and its treatment.
Topics: Animals; Citalopram; Corticosterone; Darkness; Depression; Disease Models, Animal; Female; Infusion | 2013 |
Upregulation of the dorsal raphe nucleus-prefrontal cortex serotonin system by chronic treatment with escitalopram in hyposerotonergic Wistar-Kyoto rats.
Topics: Animals; Anxiety; Citalopram; Disease Models, Animal; Exploratory Behavior; Feeding Behavior; Food P | 2013 |
Reappraisal of spontaneous stereotypy in the deer mouse as an animal model of obsessive-compulsive disorder (OCD): response to escitalopram treatment and basal serotonin transporter (SERT) density.
Topics: Animals; Brain; Citalopram; Disease Models, Animal; Obsessive-Compulsive Disorder; Peromyscus; Selec | 2013 |
Serotonin 2C receptor antagonists induce fast-onset antidepressant effects.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Chronic Disease; Citalopram; Cycl | 2014 |
A novel herbal treatment reduces depressive-like behaviors and increases BDNF levels in the brain of stressed mice.
Topics: Animals; Brain Chemistry; Brain-Derived Neurotrophic Factor; Citalopram; Crataegus; Depression; Dise | 2014 |
The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram.
Topics: 5-Hydroxytryptophan; Animals; Antidepressive Agents; Behavior, Animal; Brain; Citalopram; Cyclospori | 2014 |
Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: evidence for direct 5-HT receptor modulation.
Topics: 5-Hydroxytryptophan; Animals; Carbidopa; Citalopram; Disease Models, Animal; Dose-Response Relations | 2014 |
Expression of genes encoding cytokines and corticotropin releasing factor are altered by citalopram in the hypothalamus of post-stroke depression rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Citalopram; Corticotropin-Releasing Hormone; Cyto | 2013 |
The discovery of Yuanzhi-1, a triterpenoid saponin derived from the traditional Chinese medicine, has antidepressant-like activity.
Topics: Animals; Antidepressive Agents; Citalopram; Cocaine; Depression; Disease Models, Animal; Female; Flu | 2014 |
Dorsal raphe neuroinflammation promotes dramatic behavioral stress dysregulation.
Topics: Animals; Citalopram; Dependovirus; Disease Models, Animal; Encephalitis; Female; Gene Expression Reg | 2014 |
Effects of chronic mild stress on the development of drug dependence in rats.
Topics: Animals; Chronic Disease; Citalopram; Depressive Disorder; Diazepam; Disease Models, Animal; Flumaze | 2014 |
Behavioural and transcriptional effects of escitalopram in the chronic escape deficit model of depression.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Body Weight; Chronic Disease; Citalopram | 2014 |
Antinociceptive activity of the new triple reuptake inhibitor NS18283 in a mouse model of chemotherapy-induced neuropathic pain.
Topics: Analgesics; Animals; Antineoplastic Agents; Behavior, Animal; Citalopram; Disease Models, Animal; Hy | 2015 |
Serotonin modulates fast ripple activity in rats with spontaneous recurrent seizures.
Topics: Animals; Catheters, Indwelling; Citalopram; Disease Models, Animal; Electrodes, Implanted; Electroen | 2014 |
Bifidobacteria exert strain-specific effects on stress-related behavior and physiology in BALB/c mice.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Bifidobacterium; Citalopram; Disease Mode | 2014 |
Chronic but not acute antidepresant treatment alters serum zinc/copper ratio under pathological/zinc-deficient conditions in mice.
Topics: Animals; Antidepressive Agents; Bupropion; Citalopram; Copper; Depression; Disease Models, Animal; I | 2014 |
The effects of escitalopram on myocardial apoptosis and the expression of Bax and Bcl-2 during myocardial ischemia/reperfusion in a model of rats with depression.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Citalopram; Depressive Disorder, Major; Disease Mode | 2014 |
Perinatal vs genetic programming of serotonin states associated with anxiety.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety Disorders; Brain; Citalopram; Disease Mod | 2015 |
The antidepressant-like pharmacological profile of Yuanzhi-1, a novel serotonin, norepinephrine and dopamine reuptake inhibitor.
Topics: Animals; Antidepressive Agents; Citalopram; Corpus Striatum; Depression; Disease Models, Animal; Dru | 2015 |
The Role of the Two-Pore Domain Potassium Channel TREK-1 in the Therapeutic Effects of Escitalopram in a Rat Model of Poststroke Depression.
Topics: Animals; Body Weight; Brain; Cell Proliferation; Citalopram; Depression; Disease Models, Animal; Exp | 2015 |
The effects of AP521, a novel anxiolytic drug, in three anxiety models and on serotonergic neural transmission in rats.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Cells, Cultured; Citalopram; Diazepam; Disease Models, Animal | 2015 |
Dopamine Receptor D2 and Associated microRNAs Are Involved in Stress Susceptibility and Resistance to Escitalopram Treatment.
Topics: Animals; Antidepressive Agents, Second-Generation; Chronic Disease; Citalopram; Corpus Striatum; Dep | 2015 |
Repeated ketamine administration redeems the time lag for citalopram's antidepressant-like effects.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depressive Disorder; Disease Models, A | 2015 |
Olanzapine augments the effect of selective serotonin reuptake inhibitors by suppressing GABAergic inhibition via antagonism of 5-HT₆ receptors in the dorsal raphe nucleus.
Topics: Animals; Antidepressive Agents; Benzodiazepines; Bicuculline; Citalopram; Depressive Disorder; Disea | 2015 |
Ozone exposure of Flinders Sensitive Line rats is a rodent translational model of neurobiological oxidative stress with relevance for depression and antidepressant response.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depression; Depressive Disorder, Major | 2015 |
Brain Histamine Is Crucial for Selective Serotonin Reuptake Inhibitors' Behavioral and Neurochemical Effects.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Animals; Antidepressive Agents; Brain; Citalopram; Cyclic AM | 2015 |
Changed Synaptic Plasticity in Neural Circuits of Depressive-Like and Escitalopram-Treated Rats.
Topics: Animals; Antidepressive Agents; Blotting, Western; Body Weight; Brain; Chronic Disease; Citalopram; | 2015 |
Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Citalopram; Disease Models, Animal; Dyskinesia, | 2015 |
Deletion of GIRK2 Subunit of GIRK Channels Alters the 5-HT1A Receptor-Mediated Signaling and Results in a Depression-Resistant Behavior.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Action Potentials; Animals; Antidepressive Agents, Second-Ge | 2015 |
The effects of gestational stress and Selective Serotonin reuptake inhibitor antidepressant treatment on structural plasticity in the postpartum brain--A translational model for postpartum depression.
Topics: Animals; Antidepressive Agents; Brain; Citalopram; Depression, Postpartum; Disease Models, Animal; F | 2016 |
Prenatal stress, regardless of concurrent escitalopram treatment, alters behavior and amygdala gene expression of adolescent female rats.
Topics: Amygdala; Animals; Anxiety; Citalopram; Corticosterone; Disease Models, Animal; Estradiol; Female; g | 2015 |
Neuroprotective effect of escitalopram oxalate in rats with chronic hypoperfusion.
Topics: Animals; Citalopram; Disease Models, Animal; Hypoxia-Ischemia, Brain; Male; Maze Learning; Memory; N | 2015 |
Amelioration of the reduced antinociceptive effect of morphine in the unpredictable chronic mild stress model mice by noradrenalin but not serotonin reuptake inhibitors.
Topics: Analgesics; Animals; Chronic Disease; Citalopram; Disease Models, Animal; Male; Maprotiline; Mice, I | 2015 |
Citalopram and sertraline exposure compromises embryonic bone development.
Topics: Animals; Apoptosis; Bone and Bones; Calcification, Physiologic; Cartilage; Cells, Cultured; Citalopr | 2016 |
Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease.
Topics: Animals; Ataxin-3; Behavior, Animal; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Citalo | 2015 |
Escitalopram Ameliorates Tau Hyperphosphorylation and Spatial Memory Deficits Induced by Protein Kinase A Activation in Sprague Dawley Rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Citalopram; Colforsin; Disease Models, Animal; En | 2015 |
Essential Contributions of Serotonin Transporter Inhibition to the Acute and Chronic Actions of Fluoxetine and Citalopram in the SERT Met172 Mouse.
Topics: Animals; Antidepressive Agents; Brain; Cell Proliferation; Cell Survival; Citalopram; Depression; Di | 2016 |
Perinatal citalopram does not prevent the effect of prenatal stress on anxiety, depressive-like behaviour and serotonergic transmission in adult rat offspring.
Topics: Animals; Anxiety; Autoreceptors; Behavior, Animal; Citalopram; Corticotropin-Releasing Hormone; Dise | 2016 |
Effects of Escitalopram on a Rat Model of Persistent Stress-Altered Hedonic Activities: Towards a New Understanding of Stress and Depression.
Topics: Age Factors; Animals; Antidepressive Agents, Second-Generation; Citalopram; Corticosterone; Depressi | 2015 |
Escitalopram reversed the traumatic stress-induced depressed and anxiety-like symptoms but not the deficits of fear memory.
Topics: Animals; Anxiety; Brain; Citalopram; Depression; Disease Models, Animal; Fear; Memory; Rats; Rats, W | 2016 |
Social behavior in deer mice as a novel interactive paradigm of relevance for obsessive-compulsive disorder (OCD).
Topics: Animals; Citalopram; Cohort Studies; Disease Models, Animal; Female; Male; Motor Activity; Obsessive | 2017 |
Traxoprodil, a selective antagonist of the NR2B subunit of the NMDA receptor, potentiates the antidepressant-like effects of certain antidepressant drugs in the forced swim test in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depression; Disease Models, Animal; Ex | 2016 |
The norepinephrine reuptake inhibitor reboxetine is more potent in treating murine narcoleptic episodes than the serotonin reuptake inhibitor escitalopram.
Topics: Adrenergic Uptake Inhibitors; Animals; Citalopram; Disease Models, Animal; Dose-Response Relationshi | 2016 |
Excessive nest building is a unique behavioural phenotype in the deer mouse model of obsessive-compulsive disorder.
Topics: Animals; Citalopram; Disease Models, Animal; Nesting Behavior; Obsessive-Compulsive Disorder; Peromy | 2016 |
Blood oxygen level-dependent signals via fMRI in the mood-regulating circuit using two animal models of depression are reversed by chronic escitalopram treatment.
Topics: Affect; Animals; Antidepressive Agents, Second-Generation; Brain; Brain Mapping; Cerebrovascular Cir | 2016 |
L-DOPA elicits non-vesicular releases of serotonin and dopamine in hemiparkinsonian rats in vivo.
Topics: Action Potentials; Animals; Antiparkinson Agents; Cholestanols; Citalopram; Disease Models, Animal; | 2016 |
Positive allosteric modulation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptors differentially modulates the behavioural effects of citalopram in mouse models of antidepressant and anxiolytic action.
Topics: Allosteric Regulation; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Citalopram; Depressi | 2016 |
Early citalopram treatment increases mortality due to left ventricular rupture in mice after myocardial infarction.
Topics: Animals; Biopsy; Citalopram; Collagen; Disease Models, Animal; Echocardiography; Heart Rupture, Post | 2016 |
Alpha7 nicotinic acetylcholine receptor agonists and PAMs as adjunctive treatment in schizophrenia. An experimental study.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Antidepressive Agents; Antipsychotic Agents; Benza | 2016 |
17β-Estradiol augments antidepressant efficacy of escitalopram in ovariectomized rats: Neuroprotective and serotonin reuptake transporter modulatory effects.
Topics: Acetylcholinesterase; Animals; Behavior, Animal; Brain-Derived Neurotrophic Factor; Citalopram; Cogn | 2016 |
Highly polygenic architecture of antidepressant treatment response: Comparative analysis of SSRI and NRI treatment in an animal model of depression.
Topics: Animals; Antidepressive Agents; Citalopram; Cyclic AMP Response Element-Binding Protein; Depression; | 2017 |
Effect of amitriptyline treatment on neurofilament-H protein in an experimental model of depression.
Topics: Acute Disease; Amitriptyline; Animals; Antidepressive Agents, Tricyclic; CA3 Region, Hippocampal; Ch | 2017 |
Effect of selective serotonin reuptake inhibitors on expression of 5-HT1AR and neurotransmitters in rats with vascular dementia.
Topics: Animals; Citalopram; Dementia, Vascular; Disease Models, Animal; Dopamine; Gene Expression Regulatio | 2016 |
Anhedonia and activity deficits in rats: impact of post-stroke depression.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Citalopram; Depression; Disease | 2009 |
Antidepressant-like effects of nicotinic acetylcholine receptor antagonists, but not agonists, in the mouse forced swim and mouse tail suspension tests.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depression; Disease Models, Animal; Fe | 2009 |
Acute citalopram has different effects on regional 5-HT synthesis in FSL, FRL, and SDP rats: an autoradiographic evaluation.
Topics: Animals; Antidepressive Agents, Second-Generation; Autoradiography; Brain; Citalopram; Depressive Di | 2008 |
Nicotine, but not mecamylamine, enhances antidepressant-like effects of citalopram and reboxetine in the mouse forced swim and tail suspension tests.
Topics: Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal | 2009 |
Effects of acute citalopram on the expression of conditioned freezing in naive versus chronic citalopram-treated rats.
Topics: Animals; Anxiety; Citalopram; Conditioning, Psychological; Disease Models, Animal; Fear; Immobilizat | 2009 |
Protective effects of antidepressants against chronic fatigue syndrome-induced behavioral changes and biochemical alterations.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior, Anima | 2009 |
Synergistic neurochemical and behavioural effects of acute intrahippocampal injection of brain-derived neurotrophic factor and antidepressants in adult mice.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Brain-Derived Neuro | 2009 |
Treatment with escitalopram but not desipramine decreases escape latency times in a learned helplessness model using juvenile rats.
Topics: Age Factors; Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Antidepressive | 2009 |
Antidepressants inhibit P2X4 receptor function: a possible involvement in neuropathic pain relief.
Topics: Action Potentials; Animals; Antidepressive Agents; Cell Line, Tumor; Citalopram; Disease Models, Ani | 2009 |
The brain 5-HT4 receptor binding is down-regulated in the Flinders Sensitive Line depression model and in response to paroxetine administration.
Topics: Animals; Antidepressive Agents, Second-Generation; Autoradiography; Brain; Citalopram; Depression; D | 2009 |
Antidepressant properties of the 5-HT4 receptor partial agonist, SL65.0155: behavioral and neurochemical studies in rats.
Topics: Analysis of Variance; Animals; Antidepressive Agents; bcl-2-Associated X Protein; Behavior, Animal; | 2009 |
The antidepressant effects of running and escitalopram are associated with levels of hippocampal NPY and Y1 receptor but not cell proliferation in a rat model of depression.
Topics: Animals; Antidepressive Agents; Bromodeoxyuridine; Cell Proliferation; Citalopram; Depression; Disea | 2010 |
Depression-like and anxiety-like behavioural aftermaths of impact accelerated traumatic brain injury in rats: a model of comorbid depression and anxiety?
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety Disorders; Brain Injuries; Citalopram; Co | 2009 |
The synergistic interaction between morphine and maprotiline after intrathecal injection in rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Amitriptyline; Analgesics, Opioid; Anima | 2009 |
A proteomic analysis of the ventral hippocampus of rats subjected to maternal separation and escitalopram treatment.
Topics: Animals; Causality; Citalopram; Depressive Disorder; Disease Models, Animal; Energy Metabolism; Fema | 2009 |
Decreased expression of serotonin 1A receptor in the dentate gyrus in association with chronic mild stress: a rat model of post-stroke depression.
Topics: Animals; Citalopram; Dentate Gyrus; Depression; Disease Models, Animal; Down-Regulation; Exploratory | 2009 |
The role of proteomics in depression research.
Topics: Animals; Antidepressive Agents; Biomarkers; Citalopram; Depressive Disorder; Disease Models, Animal; | 2010 |
Differential effects of acute and repeated citalopram in mouse models of anxiety and depression.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antidepressive Agents, Second-Generation; Anxiety; | 2010 |
Early-life stress and antidepressant treatment involve synaptic signaling and Erk kinases in a gene-environment model of depression.
Topics: Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Citalopram; Depression; Disease | 2010 |
Notch1 signaling related hippocampal neurogenesis in adult poststroke depression rats: a valid index for an efficient combined citalopram and WAY100635 pharmacotherapy.
Topics: Animals; Behavior, Animal; Citalopram; Depression; Disease Models, Animal; Drug Evaluation, Preclini | 2010 |
Hippocampal GABAergic dysfunction in a rat chronic mild stress model of depression.
Topics: Action Potentials; Animals; Antidepressive Agents, Second-Generation; Citalopram; Dentate Gyrus; Dep | 2011 |
Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease.
Topics: 5,7-Dihydroxytryptamine; Animals; Antiparkinson Agents; Brain; Citalopram; Cobra Neurotoxin Proteins | 2010 |
The 5-HT(7) receptor as a mediator and modulator of antidepressant-like behavior.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Corticosterone; Depr | 2010 |
Aging impairs the antidepressant-like response to citalopram in male rats.
Topics: Aging; Animals; Antidepressive Agents; Citalopram; Depression; Disease Models, Animal; Drinking; Foo | 2010 |
Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Cells, Cultured; | 2010 |
Estradiol valerate elicits antidepressant-like effects in middle-aged female rats under chronic mild stress.
Topics: Aging; Animals; Antidepressive Agents; Chronic Disease; Citalopram; Conditioning, Operant; Depressio | 2010 |
Potential role of glutamate neurotransmission in the pathogenesis of ischemic brain damage and of depression. Effects of L-kynurenine on the survival of the hippocampal neurons and on the corticocerebral blood flow in ischemic animal models.
Topics: Animals; Brain Ischemia; Cell Survival; Cerebrovascular Circulation; Chromatography, High Pressure L | 2010 |
Early-life stress and antidepressants modulate peripheral biomarkers in a gene-environment rat model of depression.
Topics: Animals; Biomarkers; Brain-Derived Neurotrophic Factor; C-Reactive Protein; Citalopram; Corticostero | 2010 |
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Topics: Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Bifidobacterium; Biogenic Mo | 2010 |
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Topics: Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Bifidobacterium; Biogenic Mo | 2010 |
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Topics: Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Bifidobacterium; Biogenic Mo | 2010 |
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Topics: Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Bifidobacterium; Biogenic Mo | 2010 |
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Topics: Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Bifidobacterium; Biogenic Mo | 2010 |
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Topics: Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Bifidobacterium; Biogenic Mo | 2010 |
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Topics: Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Bifidobacterium; Biogenic Mo | 2010 |
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Topics: Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Bifidobacterium; Biogenic Mo | 2010 |
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Topics: Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Bifidobacterium; Biogenic Mo | 2010 |
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Topics: Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Bifidobacterium; Biogenic Mo | 2010 |
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Topics: Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Bifidobacterium; Biogenic Mo | 2010 |
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Topics: Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Bifidobacterium; Biogenic Mo | 2010 |
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Topics: Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Bifidobacterium; Biogenic Mo | 2010 |
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Topics: Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Bifidobacterium; Biogenic Mo | 2010 |
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Topics: Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Bifidobacterium; Biogenic Mo | 2010 |
Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.
Topics: Animals; Antidepressive Agents; Arginine Vasopressin; Behavior, Animal; Bifidobacterium; Biogenic Mo | 2010 |
Interactions of corticotropin-releasing factor, urocortin and citalopram in a primate model of stress-induced amenorrhea.
Topics: Amenorrhea; Animals; Citalopram; Corticotropin-Releasing Hormone; Disease Models, Animal; Drug Inter | 2010 |
Chronic escitalopram treatment restores spatial learning, monoamine levels, and hippocampal long-term potentiation in an animal model of depression.
Topics: Acetylcholinesterase; Analysis of Variance; Animals; Animals, Newborn; Antidepressive Agents, Second | 2011 |
Escitalopram affects cytoskeleton and synaptic plasticity pathways in a rat gene-environment interaction model of depression as revealed by proteomics. Part II: environmental challenge.
Topics: Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Citalopram; Cytoskeleton; Depre | 2011 |
Escitalopram modulates neuron-remodelling proteins in a rat gene-environment interaction model of depression as revealed by proteomics. Part I: genetic background.
Topics: Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Citalopram; Depression; Disease | 2011 |
Antidepressant response to chronic citalopram treatment in eight inbred mouse strains.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Citalopram; Depression; Disease | 2011 |
Emotional memory impairments in a genetic rat model of depression: involvement of 5-HT/MEK/Arc signaling in restoration.
Topics: AIDS-Related Complex; Analysis of Variance; Animals; Avoidance Learning; Benzopyrans; Brain-Derived | 2012 |
The role of 5-HT(3) receptors in the additive anticonvulsant effects of citalopram and morphine on pentylenetetrazole-induced clonic seizures in mice.
Topics: Analysis of Variance; Animals; Anticonvulsants; Biguanides; Citalopram; Disease Models, Animal; Dose | 2011 |
Comparison of the depression-like behavior and serotonergic system between Wistar and Wistar-Kyoto rat strains.
Topics: Animals; Antidepressive Agents, Second-Generation; Citalopram; Depression; Disease Models, Animal; R | 2011 |
Antidepressant treatment is associated with epigenetic alterations in the promoter of P11 in a genetic model of depression.
Topics: Animals; Annexin A2; Citalopram; Depressive Disorder; Disease Models, Animal; DNA (Cytosine-5-)-Meth | 2012 |
Targeting the BH3-interacting domain death agonist to develop mechanistically unique antidepressants.
Topics: Aniline Compounds; Animals; Antidepressive Agents; Apoptosis Inducing Factor; Apoptosis Regulatory P | 2012 |
Effects of venlafaxine and escitalopram treatments on NMDA receptors in the rat depression model.
Topics: Animals; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Depression; Disease Mo | 2011 |
Escitalopram reduces circulating pro-inflammatory cytokines and improves depressive behavior without affecting sleep in a rat model of post-cardiac infarct depression.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Citalopram; Cytokines; Depr | 2011 |
Citalopram-mediated anxiolysis and differing neurobiological responses in both sexes of a genetic model of depression.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disor | 2011 |
Increased numbers of orexin/hypocretin neurons in a genetic rat depression model.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Body Weight; Citalopram; Depres | 2011 |
Biomarkers of anhedonic-like behavior, antidepressant drug refraction, and stress resilience in a rat model of depression.
Topics: Anhedonia; Animals; Biomarkers; Citalopram; Depression; Disease Models, Animal; Drug Resistance; Eat | 2011 |
Combined α7 nicotinic acetylcholine receptor agonism and partial serotonin transporter inhibition produce antidepressant-like effects in the mouse forced swim and tail suspension tests: a comparison of SSR180711 and PNU-282987.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Antidepressive Agents; Behavior, Animal; Benzamide | 2012 |
Learning and memory alterations are associated with hippocampal N-acetylaspartate in a rat model of depression as measured by 1H-MRS.
Topics: Animals; Aspartic Acid; Behavior, Animal; Citalopram; Creatine; Depression; Disease Models, Animal; | 2011 |
The selective serotonin reuptake inhibitor, escitalopram, enhances inhibition of prepotent responding and spatial reversal learning.
Topics: Animals; Anxiety; Behavior, Animal; Citalopram; Disease Models, Animal; Dose-Response Relationship, | 2012 |
Endogenous ciliary neurotrophic factor modulates anxiety and depressive-like behavior.
Topics: Amitriptyline; Animals; Anxiety; Biogenic Monoamines; Cell Count; Ciliary Neurotrophic Factor; Cital | 2012 |
Synergistic antidepressant-like action of gaboxadol and escitalopram.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Dentate Gyrus; Depression; Disease Mod | 2012 |
Antidepressants reduce extinction-induced withdrawal and biting behaviors: a model for depressive-like behavior.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Disease Models, Animal; Extinction, Psycholo | 2012 |
The effect of citalopram on midbrain CRF receptors 1 and 2 in a primate model of stress-induced amenorrhea.
Topics: Amenorrhea; Animals; Citalopram; Disease Models, Animal; Female; Gene Expression; Macaca fasciculari | 2012 |
The antidepressants citalopram and reboxetine reduce seizure frequency in rats with chronic epilepsy.
Topics: Animals; Antidepressive Agents; Citalopram; Disease Models, Animal; Dose-Response Relationship, Drug | 2012 |
Exofocal dopaminergic degeneration as antidepressant target in mouse model of poststroke depression.
Topics: Animals; Brain-Derived Neurotrophic Factor; Citalopram; Corticosterone; Depression; Disease Models, | 2012 |
Interaction of morphine and selective serotonin receptor inhibitors in rats experiencing inflammatory pain.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Citalopram; Disease Models, Animal; Hyperalgesia; Inf | 2012 |
Chronic psychosocial stress and citalopram modulate the expression of the glial proteins GFAP and NDRG2 in the hippocampus.
Topics: Animals; Antidepressive Agents, Second-Generation; Astrocytes; Behavior, Animal; Chronic Disease; Ci | 2012 |
Quetiapine ameliorates stress-induced cognitive inflexibility in rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Antidepressive Agents, Second-Generation; Behavior | 2013 |
Citalopram decreases tryptophan 2,3-dioxygenase activity and brain 5-HT turnover in swim stressed rats.
Topics: Amygdala; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Citalopram; Corticost | 2012 |
Distance from source of reward as a marker for extinction-induced "despair": modulation by the antidepressants clomipramine and citalopram.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Citalopram; Clomipramine; Conditioning, Operan | 2012 |
Drug-drug conditioning between citalopram and haloperidol or olanzapine in a conditioned avoidance response model: implications for polypharmacy in schizophrenia.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Benzodiazepines; Citalopram; Conditioning, Psycho | 2012 |
Behavioral changes after maternal separation are reversed by chronic constant light treatment.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Citalopram; Dep | 2012 |
Spinal cord injury induces serotonin supersensitivity without increasing intrinsic excitability of mouse V2a interneurons.
Topics: Animals; Biophysical Phenomena; Citalopram; Disease Models, Animal; Dose-Response Relationship, Drug | 2012 |
Antidepressant-dependent mRNA changes in mouse associated with hippocampal neurogenesis in a mouse model of depression.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Disease Models, Animal; Hippocampus; Mice; N | 2012 |
Vesicular signalling and immune modulation as hedonic fingerprints: proteomic profiling in the chronic mild stress depression model.
Topics: Anhedonia; Animals; Citalopram; Depression; Disease Models, Animal; Hippocampus; Immune System; Lase | 2012 |
Increasing brain serotonin corrects CO2 chemosensitivity in methyl-CpG-binding protein 2 (Mecp2)-deficient mice.
Topics: Animals; Apnea; Brain; Carbon Dioxide; Citalopram; Disease Models, Animal; Female; In Vitro Techniqu | 2013 |
Cognitive impairments from developmental exposure to serotonergic drugs: citalopram and MDMA.
Topics: Animals; Animals, Newborn; Body Weight; Citalopram; Cognition Disorders; Disease Models, Animal; Fem | 2013 |
Comet-FISH studies for evaluation of genetic damage of citalopram in somatic cells of the mouse.
Topics: Administration, Oral; Animals; Bone Marrow; Centromere; Citalopram; Colchicine; Comet Assay; Disease | 2013 |
Effect of YM992, a novel antidepressant with selective serotonin re-uptake inhibitory and 5-HT 2A receptor antagonistic activity, on a marble-burying behavior test as an obsessive-compulsive disorder model.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Disease Models, Animal; Dose-Response | 2002 |
Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities.
Topics: Action Potentials; Aggression; Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generatio | 2003 |
Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension.
Topics: Analysis of Variance; Animals; Carrier Proteins; Chronic Disease; Citalopram; Disease Models, Animal | 2003 |
Antidepressant-like effects in various mice strains in the tail suspension test.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Behavior, An | 2003 |
R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model.
Topics: Animals; Citalopram; Depressive Disorder; Disease Models, Animal; Dose-Response Relationship, Drug; | 2003 |
Anxiolytic-like effects of escitalopram, citalopram, and R-citalopram in maternally separated mouse pups.
Topics: Animals; Anti-Anxiety Agents; Anxiety, Separation; Body Temperature; Citalopram; Disease Models, Ani | 2004 |
5-HT2C receptors inhibit and 5-HT1A receptors activate the generation of spike-wave discharges in a genetic rat model of absence epilepsy.
Topics: Action Potentials; Aminopyridines; Animals; Citalopram; Disease Models, Animal; Dose-Response Relati | 2003 |
Antidepressant effects of citalopram and CRF receptor antagonist CP-154,526 in a rat model of depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depression; Disease Models, Animal; Do | 2004 |
Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain.
Topics: Acute Disease; Amitriptyline; Analgesics; Animals; Antidepressive Agents; Chronic Disease; Citalopra | 2005 |
Genotype-dependent activity of tryptophan hydroxylase-2 determines the response to citalopram in a mouse model of depression.
Topics: Animals; Antidepressive Agents, Second-Generation; Citalopram; Depression; Disease Models, Animal; D | 2005 |
Early life trauma decreases glucocorticoid receptors in rat dentate gyrus upon adult re-stress: reversal by escitalopram.
Topics: Aging; Animals; Citalopram; Dentate Gyrus; Disease Models, Animal; Down-Regulation; Glucocorticoids; | 2006 |
Citalopram counteracts depressive-like symptoms evoked by chronic social stress in rats.
Topics: Administration, Oral; Animals; Antidepressive Agents; Citalopram; Depression; Disease Models, Animal | 2006 |
Adult life behavioral consequences of early maternal separation are alleviated by escitalopram treatment in a rat model of depression.
Topics: Age Factors; Analysis of Variance; Animals; Animals, Newborn; Antidepressive Agents, Second-Generati | 2006 |
Hippocampal cytogenesis correlates to escitalopram-mediated recovery in a chronic mild stress rat model of depression.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Bromodeox | 2006 |
Neonatal citalopram exposure produces lasting changes in behavior which are reversed by adult imipramine treatment.
Topics: Adrenergic Uptake Inhibitors; Animals; Animals, Newborn; Antidepressive Agents, Tricyclic; Behavior, | 2006 |
Target brain sites of the anxiolytic effect of citalopram, a selective serotonin reuptake inhibitor.
Topics: Amygdala; Animals; Anti-Anxiety Agents; Anxiety; Citalopram; Conditioning, Psychological; Disease Mo | 2006 |
Antidepressant-like activity of selective serotonin reuptake inhibitors combined with a NK1 receptor antagonist in the mouse forced swimming test.
Topics: Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Antidepressive Agents; Citalopram; Depr | 2006 |
Long-term behavioral changes after cessation of chronic antidepressant treatment in olfactory bulbectomized rats.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depression; Dise | 2007 |
Decreased sensitivity to thermal pain in rats bred for high anxiety-related behaviour is attenuated by citalopram or diazepam treatment.
Topics: Analysis of Variance; Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiet | 2007 |
Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats.
Topics: Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Anim | 2007 |
[Establishment of rat model of post-stroke depression and the effects of citalopram on behavior thereof].
Topics: Animals; Behavior, Animal; Brain Ischemia; Citalopram; Depressive Disorder; Disease Models, Animal; | 2007 |
Rat behavior after chronic variable stress and partial lesioning of 5-HT-ergic neurotransmission: effects of citalopram.
Topics: Analysis of Variance; Animals; Anxiety; Behavior, Animal; Biogenic Monoamines; Brain Injuries; Cital | 2008 |
Effects of citalopram and fluoxetine on the corticocerebral blood flow in conscious rabbits.
Topics: Animals; Antidepressive Agents, Second-Generation; Blood Pressure; Brain Ischemia; Carotid Arteries; | 2007 |
Proteomic investigation of the ventral rat hippocampus links DRP-2 to escitalopram treatment resistance and SNAP to stress resilience in the chronic mild stress model of depression.
Topics: Animal Feed; Animals; Citalopram; Cytoskeletal Proteins; Depression; Disease Models, Animal; Drug Re | 2007 |
Molecular pathways associated with stress resilience and drug resistance in the chronic mild stress rat model of depression: a gene expression study.
Topics: Animals; Antidepressive Agents, Second-Generation; Citalopram; Depression; Disease Models, Animal; D | 2007 |
Long-term citalopram maintenance in mice: selective reduction of alcohol-heightened aggression.
Topics: Aggression; Animals; Behavior, Animal; Central Nervous System Depressants; Citalopram; Conditioning, | 2008 |
WFS1 gene as a putative biomarker for development of post-traumatic syndrome in an animal model.
Topics: Amygdala; Animals; Biomarkers; Citalopram; Disease Models, Animal; Freezing Reaction, Cataleptic; Ge | 2009 |
The number of granule cells in rat hippocampus is reduced after chronic mild stress and re-established after chronic escitalopram treatment.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Cell Coun | 2008 |
Juvenile rats in the forced-swim test model the human response to antidepressant treatment for pediatric depression.
Topics: Adolescent; Age Factors; Animals; Antidepressive Agents; Child; Citalopram; Depressive Disorder; Des | 2008 |
Hippocampal neurogenesis and behavioural studies on adult ischemic rat response to chronic mild stress.
Topics: Adaptation, Physiological; Adaptation, Psychological; Animals; Antidepressive Agents, Second-Generat | 2008 |
Serotonergic mediation of the antidepressant-like effect of the green leaves odor in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain Chemistry; Citalopram; Depression; Disease M | 2008 |
Lasting syndrome of depression produced by reduction in serotonin uptake during postnatal development: evidence from sleep, stress, and behavior.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Animals, Newborn; Antidepress | 2008 |
Escitalopram reduces increased hippocampal cytogenesis in a genetic rat depression model.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Bromodeoxyuridine; Cell Pro | 2008 |
Chronic administration of citalopram inhibited El mouse convulsions and decreased monoamine oxidase-A activity.
Topics: Administration, Oral; Animals; Anticonvulsants; Brain; Citalopram; Disease Models, Animal; Epilepsy; | 1994 |
Electrophysiological activity of raphe dorsalis serotoninergic neurones in a possible model of endogenous depression.
Topics: Animals; Antidepressive Agents; Citalopram; Clomipramine; Disease Models, Animal; Male; Membrane Pot | 1995 |
The effect of 5-HT1A receptor ligands in a chronic mild stress model of depression.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Citalopram; Depressive Disorder; Disease Models, An | 1995 |
Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test.
Topics: Animals; Antidepressive Agents; Buspirone; Citalopram; Depression; Disease Models, Animal; Dose-Resp | 1998 |
Use of the selective serotonin reuptake inhibitor citalopram in a possible animal analogue of obsessive-compulsive disorder.
Topics: Animals; Citalopram; Dermatitis; Disease Models, Animal; Dogs; Female; Follow-Up Studies; Grooming; | 1998 |
Comparison of the effects of the selective serotonin-reuptake inhibitors fluoxetine, paroxetine, citalopram and fluvoxamine in alcohol-preferring cAA rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Citalopram; Disease Models, Animal; Eating; Ethanol; Female; | 1999 |
Behavioural consequences of repeated social defeat in the mouse: preliminary evaluation of a potential animal model of depression.
Topics: Aggression; Alcohol Drinking; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; B | 1999 |
S-enantiomer of the selective serotonin reuptake inhibitor citalopram compared with racemate citalopram (S+R).
Topics: Animals; Antidepressive Agents, Second-Generation; Citalopram; Depression; Disease Models, Animal; D | 2001 |
Behavioural and biochemical studies of citalopram and WAY 100635 in rat chronic mild stress model.
Topics: Animals; Cerebral Cortex; Chronic Disease; Citalopram; Disease Models, Animal; Drug Therapy, Combina | 2002 |
[Experimental model of depression: neurochemical changes and the effects of imipramine and citalopram].
Topics: Animals; Antidepressive Agents; Brain; Catecholamines; Citalopram; Depression; Disease Models, Anima | 1992 |